



- (51) **International Patent Classification:**
C12N 9/50 (2006.01) C12N 9/00 (2006.01)
- (21) **International Application Number:**
PCT/US2015/057125
- (22) **International Filing Date:**
23 October 2015 (23.10.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/074,494 3 November 2014 (03.11.2014) US
62/209,010 24 August 2015 (24.08.2015) US
- (71) **Applicants:** MERCK PATENT GMBH [DE/DE]; Frankfurt Strasse 250, 64293 Darmstadt (DE). ZERA INTEIN PROTEIN SOLUTIONS SL [ES/ES]; C/Cavallers 50, 08034 Barcelona (ES).
- (72) **Inventors:** ZILLMANN, Martin; c/o Emd Millipore Corporation, 290 Concord Road, Billerica, MA 01821 (US). ORLANDO, Joe; c/o Emd Millipore Corporation, 290 Concord Road, Billerica, MA 01821 (US).
- (74) **Agents:** CARROLL, Alice, O. et al.; Hamilton, Brook, Smith & Reynolds, P.C., 530 Virginia Rd, P.O. Box 9133, Concord, MA 01742-9133 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))



WO 2016/073228 A1

(54) **Title:** SOLUBLE INTEIN FUSION PROTEINS AND METHODS FOR PURIFYING BIOMOLECULES

(57) **Abstract:** The present invention relates to fusion proteins comprising an N-intein polypeptide and an N-intein solubilization partner, and affinity chromatography matrices comprising such fusion proteins, as well as methods of using same.

SOLUBLE INTEIN FUSION PROTEINS AND METHODS FOR PURIFYING BIOMOLECULES

RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62/074,494, filed on November 3, 2014, and U.S. Provisional Application No. 62/209,010, filed on August 24, 2015. The entire teachings of the above applications are incorporated herein by reference.

FIELD OF THE INVENTION

[0002] The present invention relates to fusion proteins comprising an N-intein polypeptide and an N-intein solubilization partner, affinity chromatography matrices comprising such fusion proteins, and methods of using such fusion proteins in protein purification and peptidic ligation processes, particularly at industrial scale.

BACKGROUND OF THE INVENTION

[0003] Protein purification methods that involve tagging a protein of interest with an affinity tag are widely used in laboratory settings for R&D applications, but have proven to be impractical for large-scale manufacturing operations. In the bioprocessing industry, only cleavable affinity tags are used to ensure that the final product does not contain the tag, which must be removed during production, typically using a site-specific protease. Removing the affinity tag requires additional process steps, which substantially increases cost and time, particularly at industrial scale. Moreover, inefficient and off-site cleavage leads to contamination of the final protein product with proteins that retain the tag and truncated protein fragments, respectively, which is not acceptable in bioprocessing applications.

[0004] Accordingly, there is a need to develop improved affinity chromatography reagents and methods that permit large-scale purification of proteins under industrial conditions.

SUMMARY OF THE INVENTION

[0005] Inteins are a class of autocatalytic enzymes that contain both protease and ligase activities. One class of inteins, termed “split inteins,” involves two complementary half inteins, termed the N-intein and C-intein, that associate selectively and extremely tightly to form an active intein enzyme (Shah N.H., *et al.*, *J. Amer. Chem. Soc.* 135: 18673-18681; Dassa B., *et al.*, *Nucl. Acids Res.*, 37:2560–2573 (2009)).

[0006] The use of inteins, including split inteins, in large-scale protein purification processes has been previously described in the prior art (see, e.g., WO 2013/045632). The use of split inteins for the chromatographic separation of proteins of interest from crude mixtures has also been described previously (see, e.g., Chinese Publication No. CN101884910; Guan D., *et al.*, *Biotech. Bioeng.* 110:2471-2481 (2013); Lu W., *et al.*, *J. Chrom. A*, 1218: 2553–2560(2011)).

[0007] However, the use of inteins in large-scale protein purification processes is hindered by their poor solubility when expressed in common expression systems, such as *E. coli*. Furthermore, a chromatography matrix that includes an intein-based affinity ligand that is covalently attached to a solid support, which is critical for efficient industrial-scale protein purification processes, has not been described.

[0008] The present invention provides soluble fusion proteins comprising an N-intein polypeptide capable of forming an active intein complex by associating with a second fusion protein comprising a C-intein polypeptide. The fusion proteins comprising an N-intein polypeptide can be covalently attached to a solid support to produce an affinity chromatography matrix that is suitable for large-scale bioprocessing applications.

[0009] Accordingly, in one embodiment, the present invention relates to a fusion protein comprising an N-intein polypeptide and an N-intein solubilization partner joined by a peptide bond. In a particular aspect of this embodiment, the N-intein solubilization partner has a molecular weight of less than about 15 kDa, an Aliphatic Index value less than about 60, and a Grand Average Hydropathy value less than -1, and enhances (e.g., increases and/or promotes) solubility of the N-intein polypeptide. In a further aspect of this embodiment, the N-intein solubilization partner comprises SEQ ID NO:15. In yet another aspect of this embodiment, the N-intein polypeptide is the GP41-1 N-intein (SEQ ID NO:1), or a variant thereof.

[0010] In another embodiment, the invention relates to an affinity chromatography matrix comprising a fusion protein comprising an N-intein polypeptide and an N-intein

solubilization partner, attached to a solid support. In a particular aspect of this embodiment, the solid support is a chromatography resin that includes a hydrophilic polyvinyl ether base.

[0011] In a further embodiment, the invention relates to a method of affinity purifying a target molecule in a sample. In one aspect of this embodiment, the method comprises a) providing a sample containing a first fusion protein comprising a C-intein polypeptide joined to a target molecule by a peptide bond; b) contacting the sample with an affinity chromatography matrix that comprises a second fusion protein, wherein the second fusion protein comprises an N-intein polypeptide joined by a peptide bond to an N-intein solubilization partner that promotes solubility of the N-intein polypeptide, under conditions in which the C-intein polypeptide in the first fusion protein selectively binds to the N-intein polypeptide in the second fusion protein to form an intein complex that is inactive; c) washing the affinity chromatography matrix containing the inactive intein complex to remove unbound contaminants; d) exposing the intein complex to conditions under which the intein complex is active and cleaves the target molecule from the C-intein polypeptide; and e) recovering the cleaved target molecule.

[0012] In yet another embodiment, the invention relates to a method of screening for a catalytically-active intein complex that is suitable for use in affinity purification. In an aspect of this embodiment, the method comprises a) contacting a first fusion protein that comprises a C-intein polypeptide joined to a target molecule (e.g., by a peptide bond or linker molecule) with a second fusion protein that comprises an N-intein polypeptide joined to an N-intein solubilization partner (e.g., by a peptide bond or linker molecule), under conditions in which the C-intein polypeptide in the first fusion protein selectively binds to the N-intein polypeptide in the second fusion protein to form an intein complex; and b) determining whether the target molecule is cleaved from the C-intein polypeptide under conditions which support intein activity, wherein the presence of the cleaved target molecule is indicative of a catalytically-active intein complex.

[0013] The N-intein fusion proteins of the present invention have improved solubility and enhanced catalytic activity, and are useful as reagents for performing large-scale protein purification (e.g., affinity chromatography) and modification processes (e.g., peptidic cleavage and ligation reactions) when partnered with the corresponding C-intein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0015] FIG. 1 is a schematic diagram depicting an exemplary affinity purification method of the invention. The method employs an exemplary affinity chromatography matrix of the invention comprising a fusion protein having an N-intein polypeptide fused to an N-intein solubilization partner that is attached to a solid support (Surface). A second fusion protein comprising a C-intein that is complementary to the N-intein in the affinity chromatography matrix is fused to the target protein to be purified (protein of interest) and any other elements required for expression, such as secretion signals. FIG. 1A shows the various components before binding of the C-intein fusion protein to the N-intein affinity chromatography matrix. FIG. 1B shows the C-intein fusion protein bound to the N-intein affinity chromatography matrix under appropriate conditions (e.g., pH, salt, oxidation/reduction) for intein association. FIG. 1C shows the components after the N- and C-exteins have been cleaved from their respective fusion proteins under appropriate conditions for catalytic activity of the intein complex.

[0016] FIG. 2A is a graph depicting the effect of fusion polarity on catalytic activity (rate of cleavage) for three candidate N-intein solubilization partners (46, 206, 246; see Table 2) that were fused to either the N-terminus (SOLP-NINT) or C-terminus (NINT-SOLP) of the GP41-1 N-intein.

[0017] FIG. 2B is a graph depicting the effect of fusion polarity on protein expression in *E. coli* for three candidate N-intein solubilization partners (46, 206, 246) that were fused to either the N-terminus (SOLP-NINT) or C-terminus (NINT-SOLP) of the GP41-1 N-intein.

[0018] FIG. 3 is a graph depicting substrate cleavage rates and soluble expression titers for seven candidate solubilization partners (46, 206, 246, 51, 138, 342, 368) that were fused to the C-terminus of the GP41-1 N-intein.

[0019] FIG. 4 is a graph depicting the correlation between calculated physical properties of candidate solubilization partners and either total (titer) or soluble (soluble titer) expression in *E. coli* of fusion proteins containing the solubilization partner fused to the C-terminus of the N-intein. mw: molecular weight; pI: isoelectric point; AI: aliphatic index; GRAVY: grand average of hydrophathy.

[0020] FIG. 5A is a chart showing the frequencies with which particular amino acids are found in roughly one hundred GP41-1 homologs at the residue corresponding to the cysteine at position 65 of the GP41-1 intein.

[0021] FIG. 5B is a chart showing the frequencies with which particular amino acids are found in roughly one hundred GP41-1 homologs at the residue corresponding to the cysteine at position 89 of the GP41-1 intein.

[0022] FIG. 6 is a graft depicting the catalytic activities (cleavage rates) of fusion proteins of solubilization partner 138 with the wild type GP41-1 N-intein containing two centrally located, naturally-occurring cysteine residues at positions 65 and 89, or variants of the GP41-1 N-intein that contain amino acid substitutions for one or both of the cysteine residues at positions 65 and 89.

[0023] FIG. 7 depicts an NMR solution structure for solubilization partner 138 (Protein Databank structure 1RYK). The protein contains four alpha helix domains, is globular, has a long unstructured coil that forms the connection to the carboxy terminus of the N-intein (circled region; N-intein not shown). The loop regions GKL and GYQ indicated by yellow highlighting were targeted for cysteine residue insertions to create the new versions (GCKL (SEQ ID NO:61), GCYQ (SEQ ID NO:62), and GCGYQ (SEQ ID NO:63)) of solubilization partner 138 (138_GKL22GCKL, 138_GYQ48GCYQ, and 138_GYQ48GCGYQ).

DETAILED DESCRIPTION OF THE INVENTION

[0024] A description of example embodiments of the invention follows.

I. Definitions

[0025] In order that the present disclosure may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.

[0026] The terms “biomolecule of interest” and “target molecule” are used interchangeably herein to refer to a biological molecule (e.g., protein), material or macromolecular assembly, which is to be, e.g., purified or removed from a mixture (e.g., a crude protein mixture). Exemplary biomolecules of interest include, for example, recombinant peptides and proteins, including antibodies (e.g., monoclonal antibodies), vaccines, viruses, and other macromolecular assemblies, such as virus-like particles and

nanoparticles that may incorporate both biomolecular and synthetic components. By way of example, biomolecules of interest can include proteins and biomolecular assemblies (e.g., produced by recombinant DNA technology), such as, e.g., hormones (e.g. insulin, human growth hormone, erythropoietin, interferons, granulocyte colony stimulating factor, tissue plasminogen activator), monoclonal antibodies (mAbs) and mAb-derivatives (e.g., bi-specific mAbs, Fabs, scFvs, shark and camelid antibodies), scaffold-derived therapeutics (e.g., DARPins, Affibodies, anticalins), therapeutic enzymes (e.g., alpha galactosidase A, alpha-L-iduronidase, N-acetylgalactosamine-4-sulfatase, glucocerebrosidase), toxins (e.g. botulinum, CRM 197, ricin), recombinant vaccines (e.g., anthrax, diphtheria, tetanus, pneumonia, hepatitis B virus, human papilloma virus), virus-like particles (e.g., hepatitis B, human papilloma, influenza, parvovirus, Norwalk viruses), as well as industrial enzymes (e.g., papain, bromelain, trypsin, proteinase K, BENZONASE™ enzyme, DENERASE™ enzyme, urease, pepsin, etc.) and diagnostic reagents (e.g., glucose and lactate dehydrogenase, DNA polymerases, alkaline phosphatase, horseradish peroxidase, restriction enzymes, hybridoma-derived antibodies, etc.). In a particular embodiment, the target molecule is an antibody (e.g., a monoclonal antibody) to a therapeutic target.

[0027] The term “fusion protein” refers to a naturally occurring, synthetic, semi-synthetic or recombinant single protein molecule that comprises all or a portion of two or more heterologous polypeptides joined by peptide bonds.

[0028] The term “peptidic”, as used herein, refers to peptides and proteins longer than two amino acids in length that may also incorporate non-amino acid molecules (e.g. chromophores, drugs, toxins, imaging contrast agents, etc.)

[0029] The term “polypeptide” refers to a polymer of amino acids, and not to a specific length; thus, peptides, oligopeptides and proteins are included within the definition of a polypeptide.

[0030] The term “split intein”, as used herein, refers to a protein, either isolated from nature or created through recombinant DNA technology, that has the following properties: (1) the protein occurs in two halves that interact with high affinity and selectivity; (2) the two halves must contain all intein sequences required for catalytic activity and may also contain appended non-intein peptidic sequences; (3) the protein has enzymatic activity only when the two halves are tightly associated; and (4) the enzymatic activity is site selective peptidic cleavage or ligation that serves to separate intein sequences from non-intein peptidic

sequences or ligate the non-intein peptidic sequences into contiguous linear or circular proteins.

[0031] The term "complementary inteins" is used herein to refer to the N-intein and C-intein portions of a split intein pair.

[0032] The term "N-intein", as used herein, refers to an intein polypeptide having homology to the N-terminal portion of a single intein polypeptide, and which associates with a complementary C-intein to form an active intein enzyme.

[0033] The term "C-intein", as used herein, refers to an intein polypeptide having homology to the C-terminal portion of a single intein polypeptide, and which associates with a complementary N-intein to form an active intein enzyme.

[0034] The term "extein", as used herein, refers to N- and C-terminal peptidic sequences that are fused to N- and C-inteins in nature and are manipulated (e.g., cleaved or ligated) through the enzymatic action of the split intein.

[0035] The term "ligand", as used herein, refers to a molecule that is capable of strong and selective interaction with another, especially when attached to a surface, such as a chromatography resin. In some embodiments of this invention, the ligand may be an N-intein fusion protein described herein.

[0036] The term "solubilization partner", as used herein, refers to a protein that, when fused to an N-intein, enhances (e.g., increases, promotes or maintains) the amount of soluble N-intein expressed in *E. coli* relative to the amount of soluble N-intein expressed in the absence of the solubilization partner. For example, in various embodiments, expressing the N-intein as a fusion protein with a solubilization partner can increase the solubility of the N-intein by at least about 10% (e.g., about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more) relative to solubility of the intein when expressed without the solubilization partner.

[0037] In one embodiment, solubilization partner E (SEQ ID NO:25) is fused to an N-intein and the solubility of the resultant fusion protein is used to provide an experimental baseline. This is particularly useful when the N-intein alone is not soluble or stable.

[0038] The term "parental molecule" or "wild-type (wt) counterpart" or "wt protein" or "wt domain," as used herein, is intended to refer to a corresponding protein (e.g., N-intein, N-intein solubilization partner), or a domain of a protein, in its substantially native form, which is generally used as a control herein.

[0039] The term "sequence identity" means that two nucleotide or amino acid sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default gap weights, share at least 70% sequence identity, or at least 80% sequence identity, or at least 85% sequence identity, or at least 90% sequence identity, or at least 95% sequence identity or more. For sequence comparison, typically one sequence acts as a reference sequence (e.g., parent sequence), to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

[0040] Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by visual inspection (see generally Ausubel *et al.*, *Current Protocols in Molecular Biology*). One example of algorithm that is suitable for determining percent sequence identity and sequence similarity is the BLAST algorithm, which is described in Altschul *et al.*, *J. Mol. Biol.* 215:403 (1990). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (publicly accessible through the National Institutes of Health NCBI internet server). Typically, default program parameters can be used to perform the sequence comparison, although customized parameters can also be used. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 (1989)).

[0041] The term "chromatography," as used herein, refers to a dynamic separation technique which separates a target molecule of interest from other molecules in the mixture and allows it to be isolated. Typically, in a chromatography method, a mobile phase (liquid or gas) transports a sample containing the target molecule of interest across or through a stationary phase (normally solid) medium. Differences in partition or affinity to the

stationary phase separate the different molecules while mobile phase carries the different molecules out at different time.

[0042] The term "affinity chromatography," as used herein, refers to a mode of chromatography where a target molecule to be separated is isolated by its interaction with a molecule (e.g., an affinity chromatography ligand according to this invention comprising an N-intein and N-intein solubilization factor) which specifically interacts with the target molecule. In one embodiment, affinity chromatography involves the addition of a sample containing a target molecule (e.g., an immunoglobulin or an Fc-containing protein) to a solid support which carries on it an N-intein-based ligand, as described herein.

[0043] The term "affinity matrix" or "affinity chromatography matrix," as used interchangeably herein, refers to a chromatographic support onto which an affinity chromatography ligand (e.g., N-intein fusion protein or a domain thereof) is attached. The ligand is capable of binding to a molecule of interest through affinity interaction (e.g., a complementary C-intein fusion protein) which is to be purified or removed from a mixture.

[0044] The term "immunoglobulin," "Ig" or "antibody" (used interchangeably herein) refers to a protein having a basic four-polypeptide chain structure consisting of two heavy and two light chains, said chains being stabilized, for example, by interchain disulfide bonds, which has the ability to specifically bind antigen. The term "single-chain immunoglobulin" or "single-chain antibody" (used interchangeably herein) refers to a protein having a two-polypeptide chain structure consisting of a heavy and a light chain, said chains being stabilized, for example, by interchain peptide linkers, which has the ability to specifically bind antigen. The term "domain" refers to a globular region of a heavy or light chain polypeptide comprising peptide loops (e.g., comprising 3 to 4 peptide loops) stabilized, for example, by .beta.-pleated sheet and/or intrachain disulfide bond. Domains are further referred to herein as "constant" or "variable", based on the relative lack of sequence variation within the domains of various class members in the case of a "constant" domain, or the significant variation within the domains of various class members in the case of a "variable" domain. Antibody or polypeptide "domains" are often referred to interchangeably in the art as antibody or polypeptide "regions". The "constant" domains of antibody light chains are referred to interchangeably as "light chain constant regions", "light chain constant domains", "CL" regions or "CL" domains. The "constant" domains of antibody heavy chains are referred to interchangeably as "heavy chain constant regions", "heavy chain constant domains", "CH" regions or "CH" domains. The "variable" domains of antibody light chains

are referred to interchangeably as "light chain variable regions", "light chain variable domains", "VL" regions or "VL" domains. The "variable" domains of antibody heavy chains are referred to interchangeably as "heavy chain variable regions", "heavy chain variable domains", "VH" regions or "VH" domains.

[0045] "Antibodies" or "immunoglobulins" may be monoclonal or polyclonal and may exist in monomeric or polymeric form, for example, IgM antibodies which exist in pentameric form and/or IgA antibodies which exist in monomeric, dimeric or multimeric form. The term "fragment" refers to a part or portion of an antibody or antibody chain comprising fewer amino acid residues than an intact or complete antibody or antibody chain. Fragments can be obtained via chemical or enzymatic treatment of an intact or complete antibody or antibody chain. Fragments can also be obtained by recombinant means. Exemplary fragments include Fab, Fab', F(ab')₂, Fc and/or Fv fragments.

[0046] The terms "polynucleotide" and "nucleic acid molecule," used interchangeably herein, refer to polymeric forms of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. These terms include a single-, double- or triple-stranded DNA, genomic DNA, cDNA, RNA, DNA-RNA hybrid, or a polymer comprising purine and pyrimidine bases, or other natural, chemically or biochemically modified, non-natural or derivatized nucleotide bases. The backbone of the polynucleotide can comprise sugars and phosphate groups (as may typically be found in RNA or DNA), or modified or substituted sugar or phosphate groups. In addition, a double-stranded polynucleotide can be obtained from the single stranded polynucleotide product of chemical synthesis either by synthesizing the complementary strand and annealing the strands under appropriate conditions, or by synthesizing the complementary strand de novo using a DNA polymerase with an appropriate primer. A nucleic acid molecule can take many different forms, e.g., a gene or gene fragment, one or more exons, one or more introns, mRNA, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as fluororibose and thioate, and nucleotide branches. As used herein, "DNA" or "nucleotide sequence" includes not only bases A, T, C and G, but also includes any of their analogs or modified forms of these bases, such as methylated nucleotides, internucleotide modifications such as uncharged linkages and thioates, use of sugar analogs, and modified and/or alternative backbone structures, such as

polyamides. In a particular embodiment, a nucleic acid molecule comprises a nucleotide sequence encoding an N-intein fusion protein or a variant thereof, as described herein.

II. Intein-based Fusion Proteins

[0047] Inteins are a class of autocatalytic enzymes discovered in 1990 that contain both protease and ligase activities that function in the natural life cycle of these molecules. It has been demonstrated that intein reagents have utility for the cleavage, ligation, and circularization of peptidic substrates. In 1998, a new class of inteins termed “split inteins” was discovered where the enzyme occurs naturally in two parts, termed the N-intein and C-intein (complementary half inteins). While split inteins have been found in a broad variety of lower prokaryotes (Zettler J., *et al.*, *FEBS Letters*, 553:909-914 (2009); Dassa B., *et al.*, *Biochemistry*, 46:322-330 (2007); Choi J., *et al.*, *J Mol Biol.* 556: 1093-1106 (2006); Caspi, *et al.*, *Mol Microbiol.* 50: 1569-1577 (2003); Liu X. and Yang J., *J Biol Chem.*, 275:26315-26318 (2003); Wu H., *et al.*, *Proc Natl Acad Sci USA.* 5:9226-9231 (1998)), no split inteins have been identified in eukaryotes (see the intein database maintained by New England Biolabs (<http://tools.neb.com/inbase/list.php>)). Two split inteins have recently been characterized that are both extremely fast and fairly promiscuous with respect to adjoining extein sequences. One class is the Npu DnaE intein (Iwai I., *et al.*, *FEBS Letters* 550: 1853-1858 (2006); Zettler J., *et al.*, *FEBS Letters*, 553:909-914 (2009)) and the other, the GP41 split inteins identified from metagenomic data (Carvajal-Vallejos P., *et al.*, *J. Biol. Chem.* 287: 28686-28696 (2012); International PCT Publication No. WO2013045632).

[0048] The N- and C-inteins, with attached exteins (the two half proteins that will be joined by intein activity), associate extremely specifically and tightly through multiple inter-domain interactions to form the active intein enzyme (Shah N.H., *et al.*, *J. Amer. Chem. Soc.* 135: 18673-18681; Dassa B., *et al.*, *Nucl. Acids Res.*, 37:2560-2573 (2009)). In addition to the ligase and protease activities present in the first class of inteins, the split inteins have utility in affinity separations due to the tight and selective interaction of the N- and C-intein domains.

[0049] The present invention is based, in part, on the discovery that expressing intein polypeptides as fusion proteins with certain heterologous proteins, referred to herein as solubilization partners, increases the solubility of the intein, thereby rendering the intein suitable as a reagent for affinity chromatography and other protein purification and modification applications that can be practiced on a small or large scale. More specifically, the invention provides highly soluble fusion proteins comprising an N-intein polypeptide and

an N-intein solubilization partner capable of forming an active intein complex by associating with a complementary C-intein polypeptide. The invention also provides fusion proteins comprising a C-intein polypeptide and a target molecule, wherein the fusion protein is capable of associating with another fusion protein comprising a complementary N-intein polypeptide and an N-intein solubilization partner.

[0050] Accordingly, in one embodiment, the present invention relates to a fusion protein comprising all, or a portion of, an N-intein polypeptide and an N-intein solubilization partner. A variety of N-intein polypeptides are known in the art. Exemplary N-inteins include the N-inteins shown in Table 1 and others described elsewhere herein. The N-inteins disclosed herein, and other N-inteins known in the art, as well as variants of such N-inteins having at least about 75% sequence identity (e.g., at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% sequence identity) to a wild type N-intein, can be included in the fusion proteins described herein.

[0051] The first amino acid in an intein N-terminal domain is typically highly conserved and can be important for the protein splicing reaction. However, in some embodiments, the first amino acid in an intein N-terminal domain (e.g., a cysteine, a serine) can be substituted with an amino acid (e.g., an amino acid other than cysteine or serine) that prevents or decreases cleavage between the intein and a heterologous polypeptide. In a particular embodiment, the first amino acid in an intein N-terminal domain is substituted with an alanine.

[0052] In a particular embodiment, the N-intein fusion proteins described herein comprise the wild type GP41-1 N-intein (SEQ ID NO:1 or SEQ ID NO: 29) or a variant thereof. Suitable variant GP41-1 N-inteins can have at least about 75% sequence identity (e.g., at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99% sequence identity) to the wild type GP41-1 N-intein (SEQ ID NO:1). Particular examples of variant GP41-1 N-inteins for inclusion in the fusion proteins of the invention include the GP41-1 variants assigned SEQ ID NOs:2-8 herein. In certain embodiments, the GP41-1 N-intein variant lacks cysteine residues. In a particular embodiment, one or more cysteine residues that occur naturally in the GP41-1 N-intein are deleted. In another embodiment, one or more cysteine residues that occur naturally in the GP41-1 N-intein (positions 7, 65 and 89 of SEQ ID NO:1) are substituted with another amino acid residue (e.g., threonine, lysine, or asparagine). In a one embodiment, the cysteine residue that occurs naturally in the GP41-1 N-intein at position 65 of SEQ ID NO:1 is

substituted with another amino acid residue (e.g., serine, threonine). In a particular embodiment, the cysteine residue at position 65 of SEQ ID NO:1 is substituted with threonine. In yet another embodiment, the cysteine residue that occurs naturally in the GP41-1 N-intein at position 89 of SEQ ID NO:1 is substituted with another amino acid residue (e.g., methionine, tyrosine). In a particular embodiment, the cysteine residue at position 89 of SEQ ID NO:1 is substituted with methionine. In some embodiments, the GP41-1 variant is the GP41-1 NINTAA_TM N-intein variant (SEQ ID NO:6) or the GP41-1 NINTAA_TK N-intein variant (SEQ ID NO:8).

[0053] In some embodiments, the GP41-1 N-intein variant lacking some or all cysteine residues are at least 2 fold, at least 3 fold, at least 4 fold, at least 5 fold, at least 6 fold, at least 7 fold, at least 8 fold, at least 9 fold, or at least 10 fold more active than the natural GP41-1 N-intein in ligation or cleavage reactions. Intein activity, either cleavage or ligation, can generally be analyzed using SDS gel electrophoresis under reducing conditions (e.g. Zettler J., Schütz V., Mootz H.D., FEBS Letters 583: 909–914, 2009; Aranko A.S., Züger S, Buchinger E, Iwai H, PLoS ONE 4: e5185, 2009). Briefly, intein reactions, generally a time course, are stopped by the addition of SDS gel loading buffer containing a reducing agent (e.g., dithiothreitol or β -mercaptoethanol), the samples are boiled to fully denature them, and then are loaded onto a polyacrylamide gel containing SDS along with appropriate protein size markers. After electrophoresis is completed, proteins in the reaction have been separated according to their molecular weights, and may be visualized by staining with traditional or fluorescent dyes. The amounts of the various intermediates and products as a function of time can be quantitated by densitometry and intensities as a function of time converted into enzymatic rates (kobs) through application of a curve fitting program.

Table 1. Exemplary GP41-1 Split Inteins and Variants Thereof

SEQ ID NO:	name	sequence
1	GP41-1 N-intein	mtrsgyCLDLKTQVQTPQGMKEISNIQVGDVLS NTGYNEVLNVFPKSKKKSYPKITLEDGKEIICSEE HLFPTQTGEMNISGGLKEGMCLYVKEgg
2	GP41-1 NINTΔA_CC N-intein variant	mtrsgyALDLKTQVQTPQGMKEISNIQVGDVLS NTGYNEVLNVFPKSKKKSYPKITLEDGKEIICSEE HLFPTQTGEMNISGGLKEGMCLYVKEgg
3	GP41-1 NINTΔA_AC N-intein variant	mtrsgyALDLKTQVQTPQGMKEISNIQVGDVLS NTGYNEVLNVFPKSKKKSYPKITLEDGKEIASE EHLFPTQTGEMNISGGLKEGMCLYVKEgg
4	GP41-1 NINTΔA_CK N-intein variant	mtrsgyALDLKTQVQTPQGMKEISNIQVGDVLS NTGYNEVLNVFPKSKKKSYPKITLEDGKEIICSEE HLFPTQTGEMNISGGLKEGMKLYVKEgg
5	GP41-1 NINTΔA_AM N-intein variant	mtrsgyALDLKTQVQTPQGMKEISNIQVGDVLS NTGYNEVLNVFPKSKKKSYPKITLEDGKEIASE EHLFPTQTGEMNISGGLKEGMMLYVKEgg
6	GP41-1 NINTΔA_TM N-intein variant	mtrsgyALDLKTQVQTPQGMKEISNIQVGDVLS NTGYNEVLNVFPKSKKKSYPKITLEDGKEIITSEE HLFPTQTGEMNISGGLKEGMMLYVKEgg
7	GP41-1 NINTΔA_AK N-intein variant	mtrsgyALDLKTQVQTPQGMKEISNIQVGDVLS NTGYNEVLNVFPKSKKKSYPKITLEDGKEIASE EHLFPTQTGEMNISGGLKEGMKLYVKEgg
8	GP41-1 NINTΔA_TK N-intein variant	mtrsgyALDLKTQVQTPQGMKEISNIQVGDVLS NTGYNEVLNVFPKSKKKSYPKITLEDGKEIITSEE HLFPTQTGEMNISGGLKEGMKLYVKEgg
9	GP41-1 C-intein (CINT)	MGKNSMMLKKILKIEELDERELIDIEVSGNHLF YANDILTHN
10	GP41-1 C-intein- thioredoxin fusion protein (CINT_TRX) (thioredoxin portion is underlined)	MGKNSMMLKKILKIEELDERELIDIEVSGNHLF YANDILTHN <u>MSDKIIHLTDDSFDTDVLKADGAI</u> <u>LVDFWAEWCGPCKMIAPILDEIADEYQGKLTV</u> <u>AKLNIDQNPGTAPKYGIRGIPTLLLKNGEVAA</u> <u>TKVGALSQQLKEFLDANLAHHHHHH</u>

For SEQ ID Nos:1-8, non-intein sequences are indicated using lower case text and intein sequences are indicated by upper case text for SEQ ID NO:1-8.

[0054] Typically, N-intein polypeptides have poor solubility when expressed in common expression systems, such as E. coli. The present invention circumvents this problem by, for example, expressing the N-intein as a fusion protein with an N-intein solubilization partner, which increases the solubility of the N-intein (e.g., when expressed in E. coli). Preferably, the N-intein solubilization partner increases the solubility of the N-intein polypeptide such that less than about 25% by mass of the resultant fusion protein is present in inclusion bodies following production in the expression system (e.g., E. coli). The percentage by mass of an expressed protein that is present in inclusion bodies following production in an expression system can be readily determined by a person of ordinary skill in the art using standard techniques and reagents.

[0055] A person of ordinary skill in the art can readily select potential solubilization partners that may increase the solubility of a given N-intein using techniques known in the art and described herein. For example, the probability of generating a soluble product upon overexpression in an expression system (e.g., *E. coli*) can be calculated using the algorithm of Wilkinson and Harrison (Wilkinson DL and Harrison RG, *Bio/Technology*, 9: 443, 1991). The prediction of whether the protein contains a functional secretion signal can be performed using the SignalP 4.1 algorithm available from the Center for Biological Sequence Analysis at the Technical University of Denmark (<http://genome.cbs.dtu.dk/services/SignalP/>). Also see methods described in Examples 1-3 disclosed herein. Ultimately, solubilization partners that provide both optimal enhancement of solubility while allowing maximal intein catalytic activity must be selected from the candidate solubilization partners through experimental screening.

[0056] N-intein solubilization partners having certain physical properties are particularly suitable for inclusion in the fusion proteins of the invention. Such physical properties include, but are not limited to, a molecular weight of less than about 15 kDa, an Aliphatic Index (AI) value less than about 60, and a GRAVY value that is less than -1. Each of these properties can be determined for a given solubilization partner by one of ordinary skill in this art using standard assays and techniques, for example, using the online ProtParam tool (<http://web.expasy.org/tools/protparam/>) that is part of the SwissProt ExPASy suite of bioinformatics tools.

[0057] The Grand average of hydropathicity (GRAVY) (Kyte J and Doolittle RF., *J. Mol. Biol.* 157:105, 1982) of a linear polypeptide sequence is calculated as the sum of hydropathy values of all amino acids, divided by the number of residues in the sequence. Increasing positive score indicates greater hydrophobicity. The calculation is based on the Kyte-Doolittle scale. GRAVY is a simple method for displaying the hydrophobic character of a protein.

Alanine	1.8	Leucine	3.8
Arginine	-4.5	Lysine	-3.9
Asparagine	-3.5	Methionine	1.9
Aspartic acid	-3.5	Phenylalanine	2.8
Cysteine	2.5	Proline	-1.6
Glutamine	-3.5	Serine	-0.8
Glutamic acid	-3.5	Threonine	-0.7
Glycine	-0.4	Tryptophan	-0.9
Histidine	-3.2	Tyrosine	-1.3
Isoleucine	4.5	Valine	4.2

[0058] In various embodiments, the N-intein fusion proteins described herein have a GRAVY value that is less than -1.

[0059] The Aliphatic Index (Ikai, AJ., *J. Biochem.* 88:1895, 1980) of a protein is defined as the relative volume occupied by aliphatic side chains (alanine, valine, isoleucine, and leucine). It may be regarded as a positive factor for the increase of thermostability of globular proteins. The aliphatic index of a protein is calculated according to the following formula: Aliphatic index = X(Ala) + a * X(Val) + b * (X(Ile) + X(Leu)). *The coefficients a and b are the relative volume of valine side chain (a = 2.9) and of Leu/Ile side chains (b = 3.9) to the side chain of alanine. The probability of generating a soluble product upon overexpression in E. coli can also be calculated using the algorithm of Wilkinson and Harrison (Wilkinson DL and Harrison RG., *Bio/Technology*, **9**: 443, 1991). Other available algorithms do not necessarily give similar results. In various embodiments, the N-intein fusion proteins described herein have an Aliphatic Index (AI) value less than about 60, and a GRAVY value that is less than -1.

[0060] Preferably, the N-intein solubilization partner has a molecular weight of less than about 15 kDa, an Aliphatic Index value less than about 60.

[0061] Examples of particular N-intein solubilization partners are disclosed in Table 2.

Table 2. Exemplary N-intein Solubilization Partners

SEQ ID NO:	Name	GID	sequence
11	Solubilization partner 46: Qin prophage; cold shock-induced protein	170081219	MREYPNGEKTHLTVMAAGFPSL TGDHKVIYVAADRHVVTSEEILE AAIRLLS
12	Solubilization partner 206: hypothetical protein ECDH10B_1576 [Escherichia coli str. K-12 substr. DH10B]	170081120	MSHLDEVIARVDAAIEESVIAH MNELLIALSDDAELSREDRYTQ QQRLRTAIAHHGRKHKEDMEA RHEQLTKGGTIL
13	Solubilization partner 246: hypothetical protein ECDH10B_1388 [Escherichia coli str. K-12 substr. DH10B]	170080950	MNKETQPIDRETLLEANKIIRE HEDTLAGIEATGVTQRNGVLVF TGDYFLDEQGLPTAKSTAVFNM FKHLAHVLSEKYHLVD
14	Solubilization partner 51: hypothetical protein ECDH10B_0422 [Escherichia coli str. K-12 substr. DH10B]	170080051	MSLENAPDDVKLAVDLIVLLEE NQIPASTVLRALDIVKRDIYEKKL TRDDEAEK
15	Solubilization partner 138: putative stress-response protein [Escherichia coli str. K-12 substr. DH10B]	170083502	MNKDEAGGNWKQFKGKVKEQ WGKLTDDDMTHIEGKRDQLVG KIQERYGYQKDQAEKEVVDWE TRNEYRW
16	Solubilization partner 138 GKL22GCKL: putative stress-response protein [Escherichia coli str. K-12 substr. DH10B]	NA	MNKDEAGGNWKQFKGKVKEQ WG <u>C</u> KLTDDDMTHIEGKRDQLV GKIQERYGYQKDQAEKEVVDW ETRNEYRW
17	Solubilization partner 138 GYQ48GCYQ: putative stress-response protein [Escherichia coli str. K-12 substr. DH10B]	NA	MNKDEAGGNWKQFKGKVKEQ WGKLTDDDMTHIEGKRDQLVG KIQERYG <u>C</u> YQKDQAEKEVVDW ETRNEYRW
18	Solubilization partner 138 GYQ48GCGY: putative stress-response protein [Escherichia coli str. K-12 substr. DH10B]	NA	MNKDEAGGNWKQFKGKVKEQ WGKLTDDDMTHIEGKRDQLVG KIQERYG <u>C</u> GYQKDQAEKEVVD WETRNEYRW
19	Solubilization partner 342: hypothetical protein ECDH10B_2487 [Escherichia coli str. K-12 substr. DH10B]	170081941	MIAEFESRILALIDGMVDHASDD ELFASGYLRGHLTLAIAELES GDHSAQAVHTTVS QSLEKAIGAG ELSPRDQALVTDMWENLFQQA SQQ
20	Solubilization partner 368: putative sigma(54)	170082737	MQLNITGNNVEITEALREFVTA KFAKLEQYFDRINQVYVVLKVE

	modulation protein [Escherichia coli str. K-12 substr. DH10B]		KVTHTSDATLHVNGGEIHASAE GQDMYAAIDGLIDKLARQLTKH KDKLKQH
21	Solubilization partner A: EspA component of the type 3 secretion system	9626250	MDTSNATSVVNVSSASSSTSTIYD LGNMSKDEVVKLFEELGVFQA AILMFSYMYQAQSNLSIAKFAD MNEASKASTTAQKMANLVDAK IADVQSSTDKNAKAKLPQDVID YINDPRNDISVTGISDLSGDLSA GDLQTVKAAISAKANNLTTVVN NSQLEIQQMSNTLNLLTSARSD VQSLQYRTISAISL GK
22	Solubilization partner B: fh8 protease from Fasciola hepatica (HiTag)	147611	MPSVEVEKLLHVLDNRNGDGKV SAEELKAFADDSKYPLDSNKIK AFIKEHDKNKDGKLDLDELVSIL SS
23	Solubilization partner C: fh8 protease from Fasciola hepatica (HiTag)	387618410	MPSVEVEKLLH
24	Solubilization partner D: glutathione S-transferase	251787291	MGQLIDGVVHDTWYDTKSTGG KFQRSASAFRNWLTADGAPGPT GKGGFAAEKDRYHLYVSLACP WAHRTLIMRKLKGLEPFISVSV VNPLMLENGWTFDDSEPGATG DTLYQHEFLYQLYLHADPHYSG RVTVPVLWDKKNHTIVSNESAE IIRMFNTAFDALGAKAGDYPP ALQPKIDELNGWIYDTVNNGVY KAGFATSQQA YDEAVAKVFESL ARLEQILGQHRYLTGNQLTEADI RLWTTLVRFDPVYVTHFKCDK HRISDYLNLYGFLRDIYQMPGIA ETVNFDIRNHYFRSHKTINPTG IISIGPWQDLDEPHGRDVRFG
25	Solubilization partner E: head-DNA stabilization protein [Enterobacteria phage lambda]	410480759	MASWSHPQFEKASKETFTHYQP QGNSDPAHTATAPGGLSAKAPA MTPLMLDTSSRKLVAWDGTTD GAAVGILAVAADQTSTLLTFYK SGTFRYEDVLWPEAASDETKKR TAFAGTAISIV
26	Solubilization partner F: maltose binding protein	218465276	MKIKTGARILALSALTTMMFSA SALAKIEEGKLVWINGDKGYN GLAEVGKKFEKDTGIKVTVEHP DKLEEKFPQVAATGDGPDIIIFW AHDRFGGYAQSGLLAEITPDKA FQDKLYPFTWDAVRYNGKLIAY PIAVEALSLIYNKDLLPNPPKTW EEIPALDKELKAKGKSALMFNL QEPYFTWPLIAADGGYAFKYEN

			GKYDIKDVGVNDNAGAKAGLTF LVDLIKNKHMNADTDYSIAEAA FNKGETAMTINGPWAWSNIDTS KVNYGVTVLPTFKGQPSKPFVG VLSAGINAASPNKELAKEFLEN YLLTDEGLEAVNKDKPLGAVAL KSYEEELAKDPRIAATMENAQK GEIMPNIPQMSAFWYAVRTAVI NAASGRQTVDEALKDAQTRITK
27	Solubilization partner G: thioredoxin	218465276	MSDKIIHLTDDSFDTDLKADG AILVDFWAEWCGPCKMIAPILD EIADEYQGKLTVAKLNIDQNP TAPKYGIRGIPTLLLFKNGEVAA TKVGALSQQLKEFLDANLA
28	Solubilization partner H: transcription termination factor NusA	387509083	MNKEILAVVEAVSNEKALPREK IFEALESALATATKKKYEQIDV RVQIDRKSDFDTFRRLVVDV VTQPTKEITLEAARYEDES DYVEDQIESVTFDRITTQTAKQV IVQKVREAERAMVVDQFREHE GEITGVVKKVNRDNISLDLGNN AEAVILREDMLPRENFRPGDRV RGLYSVRPEARQAQLFVTRSK PEMLIELFRIEVEIGEEVIEIKAA ARDPGSRKIAVKTNDKRIDPV GACVGMRGARVQAVSTELGGE RIDIVLWDDNPAQFVINAMAPA DVASIVVDEDKHTMDIAVEAGN LAQAIGRNGQNVRLASQLSGWE LNVMTVDDLQAKHQAEAAHAI DTFTKYLDIDEDFATVLVEEGFS TLEELAYVPMKELLEIEGLDEPT VEALRERAKNALATIAQAQEE LGDNKPADDLLNLEGVDRDLAF KLAARGVCTLEDLAEQGIDDLA DIEGLTDEKAGALIMAARNICW FGDEA

“GID” refers to the GenBank ID (<http://www.ncbi.nlm.nih.gov/genbank>). Solubilization partners A-H are known solubilization partners, many of which have been incorporated into commercially available fusion systems to increase the yield and solubility of recombinant proteins produced in E. coli. Amino acids that have been artificially substituted or inserted into the parent sequence are highlighted in bold and underlined.

[0062] In a particular embodiment, the N-intein solubilization partner is, or comprises, all or a portion of solubilization partner 138 (SEQ ID NO:15), or a variant thereof (e.g., solubilization partner 138 GKL22GCKL (SEQ ID NO:16); solubilization partner 138 GYQ48GCYQ (SEQ ID NO:17); solubilization partner 138 GYQ48GCGY (SEQ ID NO:18)).

[0063] Methods of preparing fusion, or chimeric, proteins are well known in the art including, but not limited to, standard recombinant DNA techniques. For example, DNA fragments coding for different protein sequences (*e.g.*, an N-intein and an N-intein solubilization partner; a C-intein and a target molecule) are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of nucleic acid fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive nucleic acid fragments that can subsequently be annealed and re-amplified to generate a chimeric nucleic acid sequence (see Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST moiety, an Fc moiety).

[0064] Preferably, the fusion protein is expressed from an encoding nucleic acid in transiently or stably transfected or transformed prokaryotic or eukaryotic host cells or organisms. Common host cells or organisms for expression of recombinant proteins include, for example, *Escherichia coli*, *Corynebacterium glutamicum*, *Pseudomonas fluorescens*, *Lactococcus lactis*, *Pichia pastoris*, *Saccharomyces cerevisiae*, *Zea maize*, *Nicotinia tabacum*, *Daucus carota*, SF9 cells, CHO cells (*e.g.*, CHO DG44 cells, CHO DXB11 cells), NS0 cells, HEK 293 cells, and whole animals such as cows and goats. In an embodiment, the N-intein fusion protein is expressed in *E. coli*. The expressed N-intein fusion protein can then be purified away from contaminating cellular proteins using conventional separation and chromatographic methods, such as clarification by depth filtration, purification by anion and cation exchange chromatography, and concentration by ultrafiltration.

[0065] The heterologous protein (*e.g.*, N-intein solubilization partner, target molecule) can be fused to either end of the intein polypeptide. In one embodiment, an N-intein solubilization partner is joined to the N-terminal end of an N-intein polypeptide. In another embodiment, an N-intein solubilization partner is joined to the C-terminal end of an N-intein polypeptide.

[0066] In some embodiments, the intein polypeptide (*e.g.*, N-intein, C-intein) and heterologous protein (*e.g.*, N-intein solubilization partner, target molecule) are linked directly via a peptide bond. In other embodiments, the fusion protein includes a spacer, or linker, molecule between the intein polypeptide (*e.g.*, N-intein, C-intein) and heterologous protein

(e.g., N-intein solubilization partner, target molecule). Suitable spacer/linker molecules are known in the art.

[0067] In the fusion proteins described herein, the intein N-terminal domain can be fused either directly (e.g., via a peptide bond) or indirectly (e.g., via a linker amino acid sequence) to a heterologous polypeptide. Thus, in some embodiments, a heterologous polypeptide is fused either directly or indirectly to the N-terminus of an intein N-terminal domain. In certain embodiments, the first amino acid of the heterologous polypeptide is selected from the group consisting of Met, Cys, Thr, Arg, Lys, Ser, Gln, His, Ala, Tyr, Phe, Asn, Trp, Val, Leu, Asp, He, Gly, Glu and Pro.

[0068] In some embodiments, the fusion protein comprises a linker between the heterologous polypeptide and the intein sequence. For example, the fusion protein can comprise a linker between the C-terminus of the heterologous protein and the N-terminus of the N-terminal domain of the intein. The linker can be, for example, from about 1 to about 10 amino acids in length. In some embodiments, the linker can be about 1 to about 5 amino acids in length. For example, the linker can contain 1, 2, 3, 4, or 5 amino acids. In some embodiments, the last amino acid of the linker contacting the heterologous polypeptide and the N-terminus of the N-terminal domain of an intein is selected from the group consisting of Met, Cys, Thr, Arg, Lys, Ser, Gln, His, Ala, Tyr, Phe, Asn, Trp, Val, Leu, Asp, Ile, Gly, Glu and Pro.

[0069] In some embodiments, the linker can comprise an extein sequence. In some embodiments, the linker can comprise a native extein sequence. In some embodiments, the extein comprises a sequence selected from the group consisting of SEQ ID NOs: 4, 8, 13, 17, 21, 25, 35, and 39 from WO201345632. In some embodiments, a linker comprising amino acids of an extein comprises, for example, the first (i.e., N-terminal) about 1 to about 5 amino acids of a sequence selected from the group consisting of SEQ ID NOs: 4, 8, 13, 17, 21, 25, 35, and 39. In some embodiments, the linker comprises about 1, 2, 3, 4, or 5 amino acids of a sequence selected from the group consisting of SEQ ID NOs: 4, 8, 13, 17, 21, 25, 35, and 39. In some embodiments, a fusion protein comprises an intein domain and an extein domain that are found together in nature (e.g., a GP41-1 N-intein and GP41-1 C-intein). In other embodiments, a fusion protein comprises an intein domain and an extein domain that is not found together with that particular intein domain in nature, also referred to herein as a "heterologous extein domain." By way of example, a fusion protein can comprise a GP41-1 intein domain and an IMPDH extein domain.

[0070] The fusion proteins of the invention can optionally further include one or more detectable labels. Labels suitable for use according to the present invention are known in the art and generally include any molecule that, by its chemical nature, and whether by direct or indirect means, provides an identifiable signal allowing detection of a protein. Thus, for example, fusion proteins may be labeled in a conventional manner, such as with specific reporter molecules, fluorophores, radioactive materials, or enzymes (*e.g.*, peroxidases, phosphatases). In a particular embodiment, the fusion proteins include one or more fluorescent dyes as detectable labels. Standard methods for modifying a protein to include a detectable label are known in the art.

[0071] In various embodiments, the invention further relates to an isolated nucleic acid which comprises a nucleotide sequence encoding a fusion protein of the invention, an expression vector comprising such nucleic acids and a host cell carrying such expression vectors.

III. Affinity Chromatography Matrices Comprising N-intein Fusion Proteins

[0072] The fusion proteins described herein containing N-intein polypeptides and N-intein solubilization partners have utility as, *inter alia*, ligands for affinity chromatography applications. Accordingly, the present invention, in certain embodiments, provides affinity chromatography matrices comprising a fusion protein comprising an N-intein polypeptide and an N-intein solubilization partner attached to a solid support.

[0073] In a particular embodiment, the solid support is a chromatography resin. In a certain embodiment, the chromatography resin includes a hydrophilic polyvinyl ether base. Suitable chromatography resins having a hydrophilic polyvinyl ether base include, but are not limited to, ESHMUNO® resins (EMD Millipore Corporation).

[0074] In another embodiment, the chromatography resin is a synthetic methacrylate-based polymeric medium (*e.g.*, beads with a particle size in the range of about 20-40 μm or about 40-90 μm). In some embodiments, the chromatography resin has carboxylic acid functionality. Suitable chromatography resins having carboxylic acid functionality include, but are not limited to, FRACTOGEL® COO resins (EMD Millipore Corporation).

[0075] Other suitable solid supports for affinity chromatography matrices of the invention can include, for example, controlled pore glass, silica, zirconium oxide, titanium oxide, agarose, polymethacrylate, polyacrylate, polyacrylamide, polyvinyl alcohol and polystyrene, as well as derivatives thereof (*e.g.*, alloys thereof).

[0076] A porous material used as a solid support may be comprised of a hydrophilic compound, a hydrophobic compound, an oleophobic compound, an oleophilic compound or any combination thereof. The porous material may be comprised of a polymer or a copolymer. Examples of suitable porous materials, include, but are not limited to polyether sulfone, polyamide, e.g., nylon, polysaccharides such as, for example, agarose and cellulose, polyacrylate, polymethacrylate, polyacrylamide, polymethacrylamide, polytetrafluoroethylene, polysulfone, polyester, polyvinylidene fluoride, polypropylene, polyethylene, polyvinyl alcohol, polycarbonate, polymer of a fluorocarbon, e.g., poly(tetrafluoroethylene-co-perfluoro(alkyl vinyl ether)), glass, silica, zirconia, titania, ceramic, metal and alloys thereof.

[0077] The porous material may be comprised of an organic or inorganic molecule or a combination of organic and inorganic molecules and may be comprised of one or more functional groups, e.g., a hydroxyl group, a thiol group, an amino group, a carbonyl group, or a carboxylic acid group, suitable for reacting, e.g., forming covalent bonds for further chemical modification, in order to covalently bind to a protein. In another embodiment, the porous material may not possess a functional group but can be coated with a layer of material that bears functional groups such as, a hydroxyl group, a thiol group, an amino acid group, a carbonyl group, or a carboxylic acid group.

[0078] In some embodiments, a conventional affinity separation matrix is used, e.g., of organic nature and based on polymers that expose a hydrophilic surface to the aqueous media used, e.g., expose hydroxy (–OH), carboxy (–COOH), carbonyl (–CHO, or RCO-R'), carboxamido (–CONH₂, possibly in N-substituted forms), amino (–NH₂, possibly in substituted form), oligo- or polyethylenoxy groups on their external and, if present, also on internal surfaces. In one embodiment, the polymers may, for instance, be based on polysaccharides, such as dextran, starch, cellulose, pullulan, agarose etc, which advantageously have been cross-linked, for instance with bisepoxides, epihalohydrins, allyl bromide, allyglycidyl ether, 1,2,3-trihalo substituted lower hydrocarbons, to provide a suitable porosity and rigidity. In another embodiment, the solid support comprises porous agarose beads. The various supports used in the present invention can be readily prepared according to standard methods known in the art, such as, for example, inverse suspension gelation described, e.g., in Hjerten, *Biochim Biophys Acta* 79(2), 393-398 (1964). Alternatively, the base matrices can be commercially available products, such as SEPHAROSE™ FastFlow media (GE Healthcare, Uppsala, Sweden). In some embodiments,

particularly advantageous for large-scale separations, the support is adapted to increase its rigidity, and hence renders the matrix more suitable for high flow rates.

[0079] Alternatively, the solid support can be based on synthetic polymers, such as polyvinyl alcohol, polyhydroxyalkyl acrylates, polyhydroxyalkyl methacrylates, polyacrylamides, polymethacrylamides etc. In case of hydrophobic polymers, such as matrices based on divinyl and monovinyl-substituted benzenes, the surface of the matrix is often hydrophilized to expose hydrophilic groups as defined above to a surrounding aqueous liquid. Such polymers can be easily produced according to standard methods, see e.g., Arshady, *Chimica e L'Industria* 70(9), 70-75 (1988). Alternatively, a commercially available product, such as SOURCE™ (GE Healthcare, Uppsala, Sweden) and POROS resin (Applied Biosystems, Foster City, CA) may be used.

[0080] In yet other embodiments, the solid support comprises a support of inorganic nature, e.g., silica, zirconium oxide, titanium oxide and alloys thereof. The surface of inorganic matrices is often modified to include suitable reactive groups. Examples include CM Zirconia (Ciphergen–BioSeptra (Cergyponoise, France)) and CPG® supports (Millipore Corporation).

[0081] In some embodiments, the solid support may, for instance, be based on zirconia, titania or silica in the form of controlled pore glass, which may be modified to either contain reactive groups and/or sustain caustic soaking, to be coupled to ligands.

[0082] Exemplary solid support formats include, but are not limited to, a bead (spherical or irregular), a hollow fiber, a solid fiber, a pad, a gel, a membrane, a cassette, a column, a chip, a slide, a plate or a monolith.

[0083] With respect to the format of a matrix, in one embodiment, it is in the form of a porous monolith. In an alternative embodiment, the matrix is in beaded or particle form that can be porous or non-porous. Matrices in beaded or particle form can be used as a packed bed or in a suspended form. Suspended forms include those known as expanded beds and pure suspensions, in which the particles or beads are free to move. In case of monoliths, packed bed and expanded beds, the separation procedure commonly follows conventional chromatography with a concentration gradient. In case of pure suspension, batch-wise mode will be used. Also, solid support in forms such as a surface, a chip, a capillary, or a filter may be used.

[0084] The matrix could also be in the form of membrane in a cartridge. The membrane could be in flat sheet, spiral, or hollow fiber format.

[0085] In certain embodiments, the solid support can be a soluble support, e.g., a soluble polymer or a water soluble polymer. Exemplary soluble supports include, but are not limited to, a bio-polymer such as, e.g., a protein or a nucleic acid. The polymer may also be a synthetic soluble polymer, such as, for example, including but not limited, to a polymer containing negatively charged groups (carboxylic or sulfonic), positively charged groups (quaternary amine, tertiary amine, secondary or primary groups), hydrophobic groups (phenyl or butyl groups), hydrophilic groups (hydroxyl, or amino groups) or a combination of the above. Exemplary synthetic soluble polymers can be found in International PCT Publication No. WO2008091740 and U.S. Publication No. US20080255027, the entire teachings of each of which are incorporated by reference herein.

[0086] In some embodiments, the solid support can include an avidin molecule (e.g., streptavidin) and the N-intein fusion protein can comprise a biotin tag (e.g., a biotin molecule covalently attached to the solubilization partner in the fusion protein), such that binding of the fusion protein to the solid support is achieved through interaction of the avidin and biotin molecules.

[0087] The N-intein fusion proteins of the invention can be attached to the solid support at only one site in the fusion protein (single point attachment) or at more than one site in the fusion protein (multipoint attachment). Preferably, the N-intein polypeptide in the fusion protein is oriented away from the solid support when the fusion protein is attached to the solid support. For example, unique reactive amino acid groups (e.g., cysteine residues) can be positioned in the solubilization partner at locations that are distal to the active region of the N-intein domain to ensure that the N-intein is directed away from the solid support.

[0088] Preferably, the site(s) (e.g., unique reactive amino acid groups) in the fusion protein that are involved in the attachment to the solid support are located exclusively in the N-intein solubilization partner. Accordingly, to achieve this, it may be necessary to modify the N-intein polypeptide to remove the amino acid that provides the unique reactive site (e.g., cysteine), for example, by deletion or substitution of such amino acids wherever they occur in the N-intein. Methods of deleting or substituting amino acids in a protein are well known in the art.

[0089] Immobilized N-intein fusion protein may be suitable for column or multi-well chromatographic separations or may be paramagnetic such that it may be captured from solution by application of a magnetic field.

[0090] Any suitable technique may be used for attaching a fusion protein described herein to a support, e.g., a solid support including those well-known in the art and described herein. For example, in some embodiments, the fusion protein may be attached to a support via conventional coupling techniques utilizing, e.g., thiol, amino and/or carboxy groups present in the fusion protein. For example, bisepoxides, epichlorohydrin, CNBr, N-hydroxysuccinimide (NHS) etc., are well-known coupling reagents. In some embodiments, a spacer is introduced between the support and the fusion protein, which improves the availability of the fusion protein and facilitates the chemical coupling of the fusion protein to the support.

[0091] Attachment of an N-intein fusion protein to a solid support can be achieved via many different ways, most of which are well known in the art, as well as those described herein. See e.g., Hermanson *et al.*, *Immobilized Affinity Ligand Techniques*, Academic Press, pp. 51-136 (1992). For example, protein ligands can be coupled to a solid support via active groups on either the surface of the solid support or the protein ligand, such as, for example, hydroxyl, thiol, epoxide, amino, carbonyl, epoxide, or carboxylic acid group. Attachment can be achieved using known chemistries including, but not limited to, use of cyanogen bromide (CNBr), N-hydroxyl succinimide ester, epoxy (bisoxirane) activation, and reductive amination.

[0092] In a particular embodiment, a chromatography resin (e.g., beads) having carboxylic acid (-COOH) or amino (-NH₂) groups is used. In a further embodiment, the chromatography resin also has hydroxyl (-OH) groups and/or other functional group that can be converted into -COOH or -NH₂ or -OH.

[0093] In some embodiments, thiol-directed protein coupling can be used to attached the N-intein fusion protein of the invention to a solid support. Thiol-directed protein coupling has been described in the literature. See, e.g., Ljungquist, *et al.*, *Eur. J. Biochem.* Vol 186, pp. 558-561 (1989). Maleimides are known to react selectively with thiol groups at pH 7.0-7.5. At pH > 8, they may also react with amine groups and, in addition, tend to hydrolyze (Greg T. Hermanson, *Bioconjugation Techniques*, Academic Press, 2008; Ian Johnson, Michelle T.Z. Spence, *Molecular Probes Handbook, A Guide to Fluorescent Probes and Labeling Technologies*, 2010). Below pH 8, iodoacetamides are also highly selective towards thiol groups (Greg T. Hermanson, *Bioconjugation Techniques*, Academic Press, 2008; Ian Johnson, Michelle T.Z. Spence, *Molecular Probes Handbook, A Guide to Fluorescent Probes and Labeling Technologies*, 2010). However, iodoacetamides are intrinsically unstable in

light and most commercially available linkers are not water soluble and/or very expensive. Since the selectivity of iodoacetamide towards thiol groups is not superior to maleimide, maleimide is generally the better choice for large scale manufacture.

[0094] In some embodiments, the N-intein ligand can be coupled to AMP or iodoacetamide activated FG-COO through a single available sulfhydryl group in the solubilization domain. The ligand density of the derivatised resin can be calculated by measuring depletion of a fusion protein bearing the C-intein from solution. To date, an unoptimized N-intein ligand density of 1 gm/liter of FG-COO has been achieved.

[0095] Many proteins have also been successfully coupled to epoxy activated resins, such as FRACTOGEL® Epoxy. The epoxide reacts with primary amino groups, hydroxyl, and sulfhydryl groups and yields very stable affinity matrices (PV Kuznetsov 1993. *Pharmaceutical Chemistry Journal* 27:439-52).

[0096] In some embodiments, the protein ligands can be coupled to a solid support via an intervening linker. The linker may comprise at least one functional group coupled to a linking moiety. The linking moiety may comprise any molecule capable of being coupled to a functional group. For example, the linking moiety may include any of an alkyl, an alkenyl or an alkynyl group. The linking moiety may comprise a carbon chain ranging from 1 to 30 carbon atoms. In some embodiments the linker may be comprised of more than 30 carbon atoms. The linking moiety may comprise at least one hetero-atom such as nitrogen, oxygen and sulfur. The linking moiety may be comprised of a branched chain, an unbranched chain or a cyclic chain. The linking moiety may be substituted with two or more functional groups.

[0097] Choosing the appropriate buffer conditions for coupling a protein ligand to a solid support is well within the capability of the skilled artisan. Suitable buffers include any non-amine containing buffer such as carbonate, bicarbonate, sulfate, phosphate and acetate buffers. When associative chemistry is used, salt concentration of the buffer will depend on the associative group used. For example, the salt concentration may be in the range of 5 nM-100 mM. Where a charged species is used, the salt concentration may be at least 5 nM but less than 0.1M, at least 5 nM but less than 0.01M, at least 5 nM but less than 0.001M. In certain embodiments, the salt concentration may be 0.01M. Where a hydrophobic species is used a high salt concentration is usually desirable. Thus the salt concentration may be greater than 0.001 M, greater than 0.01 M, or greater than 0.1 M.

[0098] In some embodiments, when associative chemistry is used, the reaction is performed at a temperature ranging from 0°C to 99°C. In certain embodiments the reaction

method is practiced at a temperature less than 60°C, less than 40°C, less than 20°C, or less than 10°C. In some embodiments the method of the invention is practiced at a temperature of about 4°C. In other embodiments the method of the invention is practiced at a temperature of 20°C.

[0099] In other embodiments, the N-intein fusion protein may be combined with various modifiers (membranes, polymeric surfaces, fluorescent or other detection labels) in combination with appropriate cross-linking or condensing chemicals to form a covalent adduct that includes the N-intein fusion protein and the modifier.

IV. Methods of Using Intein-based Fusion Proteins of the Invention

[00100] The fusion proteins described herein containing N-intein polypeptides and N-intein solubilization partners, and the affinity chromatography matrices comprising such fusion proteins, have utility, *inter alia*, in affinity purification methods, methods of screening for active split intein complexes suitable for use in affinity purification methods, and peptidic cleavage and ligation methods, as described further herein.

[00101] Accordingly, the present invention, in certain embodiments, relates to a method of affinity purifying a target molecule in a sample. In one aspect of this embodiment, the method comprises a) providing a sample containing a first fusion protein comprising a C-intein polypeptide joined to a target molecule by a peptide bond; b) contacting the sample with an affinity chromatography matrix that comprises a second fusion protein, wherein the second fusion protein comprises an N-intein polypeptide joined by a peptide bond to an N-intein solubilization partner that promotes solubility of the N-intein polypeptide, under conditions in which the C-intein polypeptide in the first fusion protein selectively binds to the N-intein polypeptide in the second fusion protein to form an intein complex that is inactive; c) washing the affinity chromatography matrix containing the inactive intein complex to remove unbound contaminants; d) exposing the intein complex to conditions under which the intein complex is active and cleaves the target molecule from the C-intein polypeptide; and e) recovering the cleaved target molecule.

[00102] The fusion protein comprising an N-intein polypeptide joined to an N-intein solubilization partner can be any of the N-intein fusion proteins described elsewhere herein.

[00103] The sample containing the fusion protein comprising a C-intein polypeptide joined to a target molecule can be any suitable sample (e.g., biological sample). In one embodiment, the sample is a crude protein preparation or mixture (e.g., a cell extract).

[00104] The target molecule can be any biomolecule of interest. By way of example, biomolecules of interest can include proteins and biomolecular assemblies (e.g., produced by recombinant DNA technology), such as, e.g., hormones (e.g. insulin, human growth hormone, erythropoietin, interferons, granulocyte colony stimulating factor, tissue plasminogen activator), monoclonal antibodies (mAbs) and mAb-derivatives (e.g., bi-specific mAbs, Fabs, scFvs, shark and camelid antibodies), scaffold-derived therapeutics (e.g., DARPins, Affibodies, anticalins), therapeutic enzymes (e.g., alpha galactosidase A, alpha-L-iduronidase, N-acetylgalactosamine-4-sulfatase, glucocerebrosidase), toxins (e.g. botulinum, CRM 197, ricin), recombinant vaccines (e.g., anthrax, diphtheria, tetanus, pneumonia, hepatitis B virus, human papilloma virus), virus-like particles (e.g., hepatitis B, human papilloma, influenza, parvovirus, Norwalk viruses), as well as industrial enzymes (e.g., papain, bromelain, trypsin, proteinase K, BENZONASE™ enzyme, DENERASE™ enzyme, urease, pepsin, etc.) and diagnostic reagents (e.g., glucose and lactate dehydrogenase, DNA polymerases, alkaline phosphatase, horseradish peroxidase, restriction enzymes, hybridoma-derived antibodies, etc.). In a particular embodiment, the target molecule is an antibody (e.g., a monoclonal antibody) to a therapeutic target.

[00105] Depending on the particular intein used (e.g., *Synechocystis* species (Ssp) DnaB, *Nostoc punctiforme* (Npu) DnaE, GP41-1), loading, washing, cleavage, and elution conditions differ significantly. Nonetheless, appropriate loading, washing, cleavage, and elution conditions for a particular intein can be readily determined by persons of ordinary skill in the art. Suitable conditions (e.g., concentration of chaotropic and reducing/oxidizing agents, metal ions (e.g., zinc, calcium, strontium, magnesium, manganese), volume excluding agents (e.g. PEG, PVP, dextran), detergents, salts, temperature, and pH) for particular inteins include, but are not limited to, conditions described herein below. For the GP41-1 intein in particular, it is known that activity is relatively unaffected by pH in the range of 6-10 (Carvajal-Vallejos P., *et al.*, *J. Biol. Chem.* 287: 28686-28696 (2012)).

[00106] Conditions under which the C-intein polypeptide in the first fusion protein selectively binds to the N-intein polypeptide in the second fusion protein to form a catalytically-inactive intein complex can be determined by one of ordinary skill in the art for a given intein. In general, for industrial scale process, changing temperature during a chromatographic separation is viewed as impractical since the change would result in a lengthy equilibration step to ensure that the column and packing temperature is uniform throughout. Exemplary binding conditions include a) a temperature in the range of about 4-

25 °C, and a buffer comprising 50 mM Tris/HCl, 300mM NaCl, 1mM EDTA, 10% (v/v) glycerol, 2 mM DTT, pH=7 (e.g., for GP41-1, see Carvajal-Vallejos P., *et al.*, *J. Biol. Chem.* 287: 28686-28696 (2012)); b) a temperature in the range of about 4-25 °C, and a buffer comprising 50 mM NaAc, 0.5 M NaCl, pH=5 (e.g., for DnaB intein, see Lu W., *et al.*, *J. Chrom. A*, 1218: 2553–2560(2011)); and c) a temperature in the range of about 4-25 °C, and a buffer comprising 0.5 M NaCl, 10 mM Tris–HCl, 0.5 mM zinc chloride, pH=8 (e.g., for Npu DnaE, see Guan D., *et al.*, *Biotech. Bioeng.* 110:2471-2481 (2013)).

[00107] Similarly, conditions that promote catalytic activity of the intein complex can vary depending on the inteins used and can be determined by one of ordinary skill in the art. Exemplary conditions for promoting catalytic intein activity include a) a buffer comprising 50 mM Tris-HCl, pH=7.0, 300 mM NaCl, 1 mM EDTA; b) a buffer comprising 0.3 M L-arginine, 5 mM EDTA, 50 mM phosphate buffer, pH=6.5; and c) a buffer comprising 0.5 M NaCl, 10 mM Tris–HCl, 50 mM DTT, pH=8.0.

[00108] In an aspect of this embodiment, the method can further comprise cleaning, regenerating and/or storing the affinity chromatography matrices of the invention. Typically, an affinity chromatography matrix can be cleaned under alkaline or acidic conditions, depending on the composition of the matrix. Suitable conditions for cleaning, regenerating, restoring and/or storing an affinity matrix can be determined by one of ordinary skill in the art.

[00109] An exemplary affinity purification method of the invention is provided in FIG. 1 and Example 10 disclosed herein.

[00110] In yet another embodiment, the invention relates to a method of screening for a catalytically-active intein complex that is suitable for use in affinity purification. In an aspect of this embodiment, the method comprises a) contacting a first fusion protein that comprises a C-intein polypeptide joined to a target molecule by a peptide bond with a second fusion protein that comprises an N-intein polypeptide joined to an N-intein solubilization partner by a peptide bond, under conditions in which the C-intein polypeptide in the first fusion protein selectively binds to the N-intein polypeptide in the second fusion protein to form an intein complex; and b) determining whether the target molecule is cleaved from the C-intein polypeptide under conditions which support intein activity, wherein the presence of the cleaved target molecule is indicative of a catalytically-active intein complex.

[00111] The N- and C-inteins employed in the method of this embodiment can be any pair of complementary split inteins, such as, for example, the split intein pairs disclosed herein (e.g., GP41-1 N-intein and C-inteins).

[00112] Conditions under which the C-intein polypeptide in the first fusion protein selectively binds to the N-intein polypeptide in the second fusion protein to form a catalytically-inactive intein complex can vary depending on the inteins used and can be determined by one of ordinary skill in the art. Exemplary binding conditions include a) a temperature in the range of about 4-25 °C, and a buffer comprising 100 mM Tris-HCl, 25 mM NaCl, 0.1mM zinc chloride, pH=9; b) a temperature in the range of about 4-25 °C, and a buffer comprising 50 mM NaAc, 0.5 M NaCl, pH=5; and c) a temperature in the range of about 4-25 °C, and a buffer comprising 0.5 M NaCl, 10 mM Tris-HCl, pH=8.

[00113] The target molecule can be any suitable target molecule, including, but not limited to, any of the target molecules disclosed herein.

EXAMPLES

Example 1: Selection of Characterization of Candidate Solubilization Partners for the GP41-1 N-intein

[00114] Using the set of the 4000+ known Escherichia proteins as a starting point, seven solubilization partners (see Table 2, SEQ ID NOs:11-15, 19, 20) were selected for testing using the following criteria:

- (1) selected proteins lacked cysteine residues;
- (2) selected proteins were predicted *in silico* to be soluble when overexpressed in E. coli;
- (3) selected proteins had a molecular weight less than 11 kDa;
- (4) selected proteins were predicted *in silico* or known not to be secreted;
- (5) where information concerning protein interactions was available, selected proteins were monomeric rather than multimeric;
- (6) where information concerning protein function was available, selected proteins were not regulatory or toxic in nature, meaning that they were not involved in the control of major cellular pathways or likely to cause the death of E. coli overexpressing them (e.g. nucleases, polymerases, etc.); and
- (7) proteins that had known NMR or X-ray crystallographic structures were favored.

[00115] Table 3 provides physical properties (molecular weight (mw), isoelectric pH (pI), probability of soluble expression in E. coli, whether protein is predicted to be secreted in E. coli, The Grand Average hYdrophobicity (GRAVY), and the Aliphatic Index (AI)) for inteins and solubilization partners assessed in this study, which were computed using publicly-available algorithms. All of the physical parameters, with the exception of the probability of solubility upon overexpression in E. coli and prediction of likelihood of secretion, were calculated using the online ProtParam tool (<http://web.expasy.org/tools/protparam/>) that is part of the SwissProt ExPASy suite of bio informatics tools. The molecular weight is given in Daltons. The pI for each protein is the pH value at which the protein has no net charge. Isoelectric point (pI) is a pH in which net charge of protein is zero. In case of proteins isoelectric point mostly depends on seven charged amino acids: glutamate (δ -carboxyl group), aspartate (β -carboxyl group), cysteine (thiol group), tyrosine (phenol group), histidine (imidazole side chains), lysine (ϵ -ammonium group) and arginine (guanidinium group). Additionally, one should take into account charge of protein terminal groups (NH₂ i COOH). Each of them has its unique acid dissociation constant referred to as pK. Moreover, net charge of the protein is in tight relation with the solution (buffer) pH. Keeping in mind this we can use Henderson-Hasselbach equation to calculate protein charge in certain pH:

Amino acid	NH ₂	COOH	C	D	E	H	K	R	Y
pKa (wikipedia)	8.2	3.65	8.18	3.9	4.07	6.04	10.54	12.48	10.46

[00116] The Grand average of hydropathicity (GRAVY) (Kyte J and Doolittle RF., J. Mol. Biol. 157:105, 1982) of a linear polypeptide sequence is calculated as the sum of hydropathy values of all amino acids, divided by the number of residues in the sequence. Increasing positive score indicates greater hydrophobicity. The calculation is based on the Kyte-Doolittle scale. GRAVY is a simple method for displaying the hydropathic character of a protein.

Alanine	1.8	Leucine	3.8
Arginine	-4.5	Lysine	-3.9
Asparagine	-3.5	Methionine	1.9
Aspartic acid	-3.5	Phenylalanine	2.8
Cysteine	2.5	Proline	-1.6
Glutamine	-3.5	Serine	-0.8
Glutamic acid	-3.5	Threonine	-0.7

Glycine	-0.4	Tryptophan	-0.9
Histidine	-3.2	Tyrosine	-1.3
Isoleucine	4.5	Valine	4.2

[00117] The Aliphatic Index (Ikai, AJ., J. Biochem. 88:1895, 1980) of a protein is defined as the relative volume occupied by aliphatic side chains (alanine, valine, isoleucine, and leucine). It may be regarded as a positive factor for the increase of thermostability of globular proteins. The aliphatic index of a protein is calculated according to the following formula: Aliphatic index = X(Ala) + a * X(Val) + b * (X(Ile) + X(Leu)). *The coefficients a and b are the relative volume of valine side chain (a = 2.9) and of Leu/Ile side chains (b = 3.9) to the side chain of alanine. The probability of generating a soluble product upon overexpression in E. coli can also be calculated using the algorithm of Wilkinson and Harrison (Wilkinson DL and Harrison RG., Bio/Technology, 9: 443, 1991). Other available algorithms do not necessarily give similar results.

[00118] The prediction of whether the protein contains a functional secretion signal was performed using the SignalP 4.1 algorithm available from the Center for Biological Sequence Analysis at the Technical University of Denmark (<http://genome.cbs.dtu.dk/services/SignalP/>).

Table 3. Physical Parameters Measured for Inteins and N-intein Solubilization Partners Used in this Study

PROTEIN	MOLECULAR WEIGHT (D)	PI	PROBABILITY SOLUBILITY IN E. COLI	SECRETED	GRAVY	ALIPHATIC INDEX
SOLUBILIZATION PARTNER 46	5639.4	5.8	74	NO	-0.086	95.7
SOLUBILIZATION PARTNER 206	8799.8	5.6	97	NO	-0.636	93.9
SOLUBILIZATION PARTNER 246	9385.6	5.4	84	NO	-0.38	89.3
SOLUBILIZATION PARTNER 51	6024.8	4.5	98	NO	-0.391	117.7
SOLUBILIZATION PARTNER 138	8325.2	5.4	69	NO	-1.526	48.0
SOLUBILIZATION PARTNER 138_ GKL22GCKL	8428.3	5.4	60	NO	-1.469	47.3
SOLUBILIZATION PARTNER 138_ GYQ48GCYQ	8428.3	5.4	60	NO	-1.469	47.3
SOLUBILIZATION PARTNER 138_ GYQ48GCGYQ	8485.4	5.4	60	NO	-1.454	46.6
SOLUBILIZATION PARTNER 342	10000	4.3	98	NO	-0.148	93.4

SOLUBILIZATION PARTNER 368	10750.2	6.5	72	NO	-0.398	95.5
GP41-1 N-INTEIN VARIANT NINTΔA_CC	10589.1	5.8	21	NO	-0.44	80.1
GP41-1 C-INTEIN (CINT)	4916.7	5.1	86	NO	-0.312	111.4
GP41-1 C-INTEIN FUSION WITH THIOREDOXIN (CINT_TRX)	17528.1	5.5	78	NO	-0.189	101.35
SOLUBILIZATION PARTNER A	20504.9	4.6	34	NO	-0.14	91.5
SOLUBILIZATION PARTNER B	7597.6	5.6	51	NO	-0.606	96.0
SOLUBILIZATION PARTNER C	1281.5	5.4	94	NO	0.127	123.6
SOLUBILIZATION PARTNER D	37389.1	6.3	42	NO	-0.388	77.9
SOLUBILIZATION PARTNER E	12740.2	5.8	41	NO	-0.299	60.4
SOLUBILIZATION PARTNER F	43387.6	5.5	40	NO	-0.251	85.4
SOLUBILIZATION PARTNER G	12629.4	5.7	74	NO	-0.143	97.6
SOLUBILIZATION PARTNER H	54870.9	4.5	95	NO	-0.278	98.0

Example 2: Creation of E. coli Protein Expression Constructs

[00119] Plasmid constructs bearing the coding sequence for the potential solubilization partners 46, 206, and 246 were fused to the coding sequence for NINTΔA_CC either via the amino or carboxy terminal amino acid of NINTΔA_CC and inserted into a version of pJ414 from DNA2.0. These constructs were transformed into competent BL21 DE3 E. coli cells using conventional methods and ampicillin resistant colonies were isolated. Production of proteins of the expected size was confirmed using SDS polyacrylamide electrophoresis (SDS PAGE).

[00120] Transformants of each of the 6 constructs were cultured in 2 mL LB containing 100 ug ampicillin/mL (LB+Amp) from a glycerol stock of BL21 DE3 E. coli cells transformed with the corresponding construct. This pre-inoculum was grown overnight at 37°C and 250 rpm and used to inoculate 200 mL of LB+Amp (1% inoculum). The culture was incubated at 37°C and 250 rpm to an OD₆₀₀ between 0.5 - 0.6. Protein expression was induced by the addition of 0.4 mM IPTG. Temperature was decreased to 30°C and the culture was incubated at this temperature and 250 rpm for 5 hours. After that time, cells were

harvested by centrifugation (4500g, 25 min, 4°C), supernatant was discarded and the cell pellet was kept at -80°C for further protein purification.

[00121] The coding region for the test substrate protein CINT_TRX was cloned into pSABAD92A (GenBank accession HM070247) and transformed into competent BL21 DE3 cells. Successful transformants were isolated on Luria broth plus 50 ug/ml carbenecillin (LB+C). Production of proteins of the expected size was confirmed using SDS PAGE. Glycerol stocks of each of the three BL21 clones/construct are stored at -80°C.

[00122] A small amount of frozen BL21 glycerol stocks was used to inoculate a 5 ml culture in LB+C at 37°C, 250 rpm. The following day, 0.1 ml of the overnight grown culture is used to inoculate 10 ml LB+C and this culture is grown at 37°C, 250 rpm to an OD₆₀₀ of 0.6 – 0.9. Cultures were induced with 0.02% arabinose at 28°C, 250 rpm for 5 hours. After induction, cells were harvested by centrifugation (4500g, 25 min, 4°C), supernatant was discarded and the cell pellet was kept at -80°C for further protein purification.

Example 3: Determination of Soluble vs Insoluble Ratio and Total Amount of Expressed Proteins

[00123] In order to determine expression yields and soluble:insoluble ratio for each construct, aliquots of grown cultures corresponding to equivalent biomasses, cultured as indicated above, were centrifuged at 5000g, 15 min, 4°C. After discarding culture supernatant, cells were resuspended in 200 uL of a solubilization buffer consisting of 50 mM Tris pH 8, 300 mM NaCl, 0.5% Triton X-100. Cells were broken by sonication (10 burst x 3, Branson 250 Sonifier, with time between each series to allow sample cooling). To separate soluble and insoluble fraction, samples were centrifuged at 16000g and 4°C for 10 min. Soluble fractions were removed to a separate tube while insoluble fractions were resuspended in 200 µL of the same solubilization buffer by sonication (using the same parameters as in the previous sonication).

[00124] Recombinant proteins in cell lysates were quantified after SDS PAGE gel after Coomassie staining using densitometric analysis of the using a curve of quantified BSA as a reference. Three different sample volumes per clone were loaded along with the BSA standard curve (6 points from 0.2 to 1.2 ug). Intensities of protein bands were determined by densitometry using the “Quantity One” (Biorad) software. A correction factor is applied for each protein considering the BSA /recombinant protein molecular weight ratio.

[00125] Concentrations for purified proteins were determined using calculated extinction coefficients and their absorbance calculated at 280 nm.

Example 4: Purification of Expressed Proteins

[00126] To purify the C-intein fusion protein CINT_TRX used as cleavage substrate throughout, *E. coli* cells expressing the protein were resuspended in buffer containing 50 mM Tris-HCl, pH=8.0, 300 mM NaCl, 0.5X CelLytic B (Sigma-Aldrich), and 20 mM imidazole. Cells were sonicated on ice for 20 min with a 30% pulsed activity cycle (Branson 250 Sonifier) and centrifuged for 30 min at 34500 g at 4°C. Soluble C-intein fusion was purified from the supernatant on His-Trap HP (GE Healthcare) columns, following manufacturer's instructions. Eluted fractions containing the purified C-intein fusion proteins were pooled, dialyzed against cleavage buffer (50 mM Tris-HCl, pH=7.0, 300 mM NaCl, 1 mM EDTA, 10% (v/v) glycerol; CB) in the presence of 2 mM DTT, and stored in aliquots at -80°C.

[00127] N-intein fusions were purified under native conditions from *E. coli* cells harboring the expression constructs. Cell pellets were resuspended in buffer containing 100 mM Tris-HCl, pH=8.0, 150 mM NaCl, and 1 mM EDTA. Cells were then sonicated on ice for 20 min with a 30% pulsed activity cycle (Branson 250 Sonifier) and centrifuged for 30 min at 34500 g at 4°C. The soluble fraction of the N-intein fusion was purified by chromatography on His-Trap HP columns as described above. Eluted fractions containing the purified protein were pooled, dialyzed against CB in the presence of 2 mM DTT and stored in aliquots at -80°C.

Example 5: Determination of Cleavage Kinetics for Expressed Proteins

[00128] In vitro reactions were performed as previously described (Carvajal-Vallejos P., *et al.*, *J. Biol. Chem.* 287: 28686, 2012). In brief, purified N- and C- fusion proteins were briefly pre-incubated separately in the corresponding test conditions. Cleavage reaction were initiated by mixing complementary N- and C- intein fusion proteins in cleavage buffer at equimolar concentrations of 5 μ M, and incubated at 25°C and 37°C. For the experiments related to this invention, the cleavage partner was always CINT_TRX. Aliquots are removed at specific time intervals, and the reaction was stopped by the addition of SDS PAGE buffer containing 8% SDS (w/v) and 20% β -mercaptoethanol (v/v), followed by 5 minutes of boiling. Reactions products were quantified by SDS PAGE (4-12% Bis-Tris gels from Novex, Invitrogen, Carlsbad, US), followed by Coomassie Brilliant Blue (Sigma) staining. Relative intensities of protein bands were determined densitometrically using the Quantity One (BioRad) program. The different cleavage products were normalized according to their corresponding molecular weight. The percentage of protein cleavage was calculated from the ratio of the cleaved products and the intein-tagged precursor CINT_TRX.

Constant rates (kobs) were determined using the GraFit software (Erithacus, Surrey, UK), by fitting the data to the equation $P=P_0(1-e^{-kt})$, where P is the amount of cleaved C-intein fusion product formed at time t, P_0 is the maximum amount of cleaved product that can be obtained (yield), e is Euler's constant, and k is the observed rate. All reactions were treated as irreversible, pre-steady state, and first-order processes under the assumption that, after rapid association of the two complementary intein fragments, cleavage of the C-intein fusion protein proceeds like a mono-molecular reaction.

Example 6: Determination of Optimal Placement and Properties for NINT Solubilization Partners

[00129] NINT Δ A_CC fusions to potential solubilization partners were created in both possible orientations (i.e. fused either to the N- or C-terminus of NINT Δ A_CC) for all solubilization partners. The six resulting constructs were expressed in E. coli and the protein produced was analysed with respect to total amount produced and solubility as previously described. In addition, protein from each construct was purified and the rate of cleavage using purified CINT_TRX as substrate was characterized. The results of this analysis are shown in FIGs. 2A and 2B. While fusion of the solubilization partner to the N-terminus of NINT Δ A_CC produces higher amounts of protein in E. coli for all constructs tested that the fusion of the solubilization partner to the C-terminus, the reverse of this trend is seen when cleavage rates are measured. Work published using a different split intein system while these studies were ongoing demonstrated a similar relationship between the location of the solubilization partner and the N-intein and N-intein activity that was explained by referring to known structural information that indicates a greater likelihood of steric interference between extein domains when the fusion is made in the opposite polarity (Guan D, Ramirez M, Chen Z., *Biotechnol Bioeng.* 110:2471, 2013).

[00130] This work was extended to include additional solubilization partners 51, 138, 342, and 368 (see Tables 2 and 3) that were distinct from previously characterized solubilization partners in terms of size and isoelectric point (pI). All of these were fused to the carboxyl terminus of NINT Δ A_CC as was shown previously with solubilization partners 46, 206, and 246 to yield fusions having the highest catalytic activity. These constructs were expressed in E. coli, purified, and analyzed for cleavage rate as described previously. The results of these analyses are presented in FIG. 3. While the solubilization partner 246 clearly has the highest activity, the best compromise between catalytic activity and soluble expression was observed for solubilization partner 138.

[00131] In order to understand the properties of solubilization partner 138 that make it effective for the solubilization of N-intein during expression in *E. coli*, the calculated protein parameters for each of the candidate solubilization in Table 3 were correlated to soluble titer in FIG. 4. While none of these parameters correlated strongly with overall expression, both AI and GRAVY values showed a negative correlation with soluble titer.

Example 7: Selection of Amino Acids for Replacement of Cysteine Residues in NINTΔA_CC

[00132] The GP41-1 N-intein isolated from natural sources contains three cysteine residues, but one had previously been replaced to give NINTΔA_CC, the parent construct for this invention. The remaining two cysteine residues contained within NINTΔA_CC were targeted for replacement so that a unique, reactive cysteine residue could be introduced into the solubilization domain for subsequent immobilization or other modification.

[00133] To identify amino acids that could be substituted for the two cysteine residues in NINTΔA_CC and still yield a stable and functional intein protein, several phylogenetic analyses were performed in which protein sequences were aligned and naturally occurring amino acid variants at positions 65 and 89 in SEQ ID NO:1 were examined. Replacement of the naturally-occurring internal cysteines in GP41-1 with other amino acids occurring at these positions in similar inteins would be expected to yield functional and/or stable GP41-1 variant proteins as natural selection has allowed these variants to persist in nature. When such an analysis is performed with N-inteins of the GP41 intein class (1, 2, 3, 4, 5, 6; Dassa B., *et al.*, *Nucl. Acids Res.*, 37:2560–2573 (2009)), the two cysteine residues at positions 65 and 89 in SEQ ID NO:1 are found to be highly conserved, suggesting that substituting these cysteines would adversely affect the activity and/or stability of the GP41-1 intein. However, if the analysis is expanded to include slightly more divergent proteins that may or may not have intein function, many proteins are identified that have homology to the *phoH* gene of the *E. coli* phosphate regulon. Roughly one hundred homologs were obtained from GenBank using the BLAST search tool and aligned with the CLUSTAL algorithm using the freeware tool, BioEdit (Hall TA., *Nucl. Acids. Symp. Ser.* 41:95, 1999). The results of this analysis are shown in FIG. 5, where the position numbering is based on NINTΔA_CC (SEQ ID NO:2). From this analysis, it is clear that threonine and alanine occur frequently at position 65 and that lysine, methionine and asparagines occur frequently at position 89, indicating that substitution of the natural cysteines with these naturally occurring amino acids should yield a stable protein.

Example 8: Screening of NINTΔA_CC Amino Acids Variants for Optimal Properties

[00134] Constructs based on NINTΔA_CC (SEQ ID NO:2) containing the amino acid substitutions shown in Table 4 were created, expressed, purified, and characterized for catalytic activity as described previously.

[00135] Cleavage rate measurements for N-intein fusions proteins made from each construct are given in FIG. 6. NINTΔA_CC parent (+cnt) is shown at the left for comparison. The amino acids at positions 65 and 89 are shown at the bottom of the figure. A threonine residue at position 65 yields N-intein fusions that have significantly more activity than the parent. Of the constructs tested, the N-intein fusion having a threonine at position 65 and a methionine at position 89 gave a construct with a catalytic rate about three times faster than the parent construct.

Table 4. GP41-1 N-intein Variants

GP41-1 N-intein variant	Sequence
NINTΔA_CC (SEQ ID NO:2)	mtrsgyALDLKTQVQTPQGMKEISNIQVGDLVLSNTGYNEVLNVFPKSKKK SYKITLEDGKEII <u>C</u> SEEHLFPTQTGEMNISGGLKEGM <u>C</u> LYVKEgg
NINTΔA_AC (SEQ ID NO:3)	mtrsgyALDLKTQVQTPQGMKEISNIQVGDLVLSNTGYNEVLNVFPKSKKK SYKITLEDGKEII <u>A</u> SEEHLFPTQTGEMNISGGLKEGM <u>C</u> LYVKEgg
NINTΔA_CK (SEQ ID NO:4)	mtrsgyALDLKTQVQTPQGMKEISNIQVGDLVLSNTGYNEVLNVFPKSKKK SYKITLEDGKEII <u>C</u> SEEHLFPTQTGEMNISGGLKEGM <u>K</u> LYVKEgg
NINTΔA_AM (SEQ ID NO:5)	mtrsgyALDLKTQVQTPQGMKEISNIQVGDLVLSNTGYNEVLNVFPKSKKK SYKITLEDGKEII <u>A</u> SEEHLFPTQTGEMNISGGLKEGM <u>M</u> LYVKEgg
NINTΔA_TM (SEQ ID NO:6)	mtrsgyALDLKTQVQTPQGMKEISNIQVGDLVLSNTGYNEVLNVFPKSKKK SYKITLEDGKEII <u>T</u> SEEHLFPTQTGEMNISGGLKEGM <u>M</u> LYVKEgg
NINTΔA_AK (SEQ ID NO:7)	mtrsgyALDLKTQVQTPQGMKEISNIQVGDLVLSNTGYNEVLNVFPKSKKK SYKITLEDGKEII <u>A</u> SEEHLFPTQTGEMNISGGLKEGM <u>K</u> LYVKEgg
NINTΔA_TK (SEQ ID NO:8)	mtrsgyALDLKTQVQTPQGMKEISNIQVGDLVLSNTGYNEVLNVFPKSKKK SYKITLEDGKEII <u>T</u> SEEHLFPTQTGEMNISGGLKEGM <u>K</u> LYVKEgg

For SEQ ID Nos:2-8, non-intein sequences are indicated using lower case text and intein sequences are indicated by upper case text.

Example 9: Strategy for the Introduction of Unique Cysteine Residues into Solubilization Partner 138

[00136] To allow chemical modification of the N-intein fusion protein without diminishing its catalytic activity the site of eventual modification should be as far removed from the

active site of the N-intein as possible. In the absence of structural information for solubilization partner 138, a reasonable approach would be to perform a phylogenetic analysis, as described above for the GP41-1 N-intein (see Example 7), determine regions of the protein that display high variability, modify these by the insertion of a cysteine, and then test all of the resulting constructs. There is, however, an NMR solution structure available for solubilization partner 138 (Protein Databank structure 1RYK), which is shown in FIG. 7. The protein contains four alpha helix domains, is globular, has a long unstructured coil that forms the connection to the carboxy terminus of the N-intein (circled region; N-intein not shown). The loop regions GKL and GYQ indicated by yellow highlighting were targeted for cysteine residue insertions to create the new versions (GCKL (SEQ ID NO:61), GCYQ (SEQ ID NO:62), and GCGYQ (SEQ ID NO:63)) of solubilization partner 138 (138_GKL22GCKL (SEQ ID NO:16), 138_GYQ48GICYQ (SEQ ID NO:17), and 138_GYQ48GCGYQ (SEQ ID NO:18)).

Example 10: Coupling of N-intein Fusion Protein (Ligand) to Chromatography Resin

[00137] A soluble fusion protein containing the solubilization partner 138_GYQ48GCGYQ (SEQ ID NO:18) fused to the carboxyl-terminus of the GP41-1 variant NINTΔA_TM (SEQ ID NO:6) is expressed from an encoding nucleic acid in *E. coli* and is subsequently separated from contaminating cellular proteins using conventional separation methods.

[00138] The purified N-intein fusion protein is then coupled to a FRACTOGEL® or ESHMUNO® chromatography resin (EMD Millipore Corporation) through the unique reactive cysteine site in the solubilization partner domain of the fusion protein using standard techniques.

[00139] In preparation for activation, 5 ml of wet FRACTOGEL® COO (FG-COO) resin are washed one time with DI water and three times with 150 mM 2-(N-morpholino)ethanesulfonic acid at pH=6.5 (MES buffer) in a Buechner funnel and transferred to a Schott glass bottle. 0.1035 gm 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide (EDC) are dissolved in 3 ml of MES buffer and added to FG-COO. The mixture is incubated for 2 min at room temperature. A solution of 0.1372 gm N-(3-aminopropyl)maleimide trifluoroacetic acid (APM) in 4 ml of MES buffer is added and the mixture is held at room temperature overnight with stirring. pH is maintained at 6.5 through titration with 1 M NaOH. For storage, the activated resin is resuspended in 150 mM NaCl containing 20% ethanol and stored in a refrigerator. For analysis of functionalization, a 50% v/v solution of

activated resin is prepared in 100 mM phosphate buffer containing 150 mM NaCl at pH=7.2 (PO buffer). 0.5 ml of activated FG-COO is mixed with 1 mL of 204 uM cysteine hydrochloride solution in PO buffer and incubated for one hour. A sample of FG-COO that has not been activated with AMP is processed in parallel as a negative control. The resin is then washed extensively with PO buffer, 0.5 M NaCl, and resuspended in 0.5 M NaCl for analysis of free sulfhydryl groups using Ellmann's reagent (5,5'-dithio-bis-(2-nitrobenzoic acid)) and known methods. A ligand density of up to 400 μmol per gram of dry resin is determined using this analysis.

Example 11: Affinity Purification of a Thioredoxin Using Intein Fusion Proteins

[00140] Resin containing immobilized N-intein fusion protein prepared according to Example 10 herein is packed into a standard chromatography column and a crude protein mixture containing the CINT_TRX fusion protein (SEQ ID NO:10), which includes the target molecule thioredoxin fused to the carboxy-terminus of the GP41-1 C-intein, is added to the column containing the immobilized N-intein fusion protein at a temperature in the range of 4-25 °C, and using a loading buffer containing 100 mM Tris-HCl, 25 mM NaCl, 0.1mM zinc chloride, pH=9 to allow strong interaction between the GP41-1 N- and C-intein domains without permitting intein catalysis.

[00141] The loaded column is then washed to remove unbound and weakly-bound contaminants using a wash buffer containing detergent (e.g., Triton X100, ND40) or salt (e.g., acetate, phosphate, chloride, sulfate salts of sodium, ammonium, or potassium).

[00142] Cleavage and elution of the thioredoxin portion of the C-intein fusion protein is accomplished by the addition of a cleavage buffer (50 mM Tris-HCl, pH=7.0, 300 mM NaCl, 1 mM EDTA). The cleaved thioredoxin is then recovered in the eluate.

Table 5. Exemplary Split Inteins and Their Sequences

Intein	SEQ ID NO:	Sequence
N-terminal domain of GP41.1	29	<u>CLDLKTQVQT</u> <u>PQGMKEISNI</u> QVGDVLVSNT GYNEVLNVFP KSKKKS Y KIT LEDGKEIICS EEHLFPTQTG EMNISGGLKE GMCLYVKE
N-terminal domain of GP41.8	30	<u>CLSLDTMVVT</u> <u>NGKAIEIRDV</u> KVGDWLESEC GPVQVTEVLP IIKQPVFEIV LKSGKKIRVS ANH K FPTKDG LKTINSGLKV GDFLRSRA
N-terminal domain of NrdJ1	31	<u>CLVGSSEIIT</u> <u>RNYGKTTIKE</u> VVEIFDNDKN IQVLAFNTH T DNIEWAPIKA AQLTRPNAEL VELEINTLHG VKTIRCTPDH PVYTKNRDYV RADELTD D DE LVVAI
N-terminal domain of IMPDH1	32	<u>CFVPGTLVNT</u> <u>ENGLKKIEEI</u> KVGDKVFSHT GKLQEVVD T L IFDRDEEII S INGIDCTKNH EFYVIDKENA NRVNEDNIHL FARWVHAEEL DMKKHLLIEL E
N-terminal domain of NrdA-2	33	<u>CLTGDAKIDV</u> <u>LIDNIPISQI</u> SLEEVVNLFN EGKEIYVLSY NIDTKEVEYK EISDAGLISE SAEVLEI I DE ETGQKIVCTP DHKVYTLNRG YVSAKDLKED DELVFS
N-terminal domain of Npu DNA-E (Genbank accession ZP_00111398)	34	<u>CLSYETEILT</u> <u>VEYGLLPIGK</u> IVEKRIECTV YSVDNNGNIY TQPVAQWHDR GEQEVFEYCL EDGSLIRATK DHKFMTVDGQ MLPIDEIFER ELDLMRVDNL PN
N-terminal domain of Ssp DNA-B (Genbank accession Q55418)	35	<u>CISGDSLISL</u> <u>ASTGKRVSIK</u> DLLDEKDFEI WAINEQTMKL ESAK V SRVFC TGK K L V YILK TRLGRTIKAT ANHRFLTIDG WKRLDELSLK EHIALPRKLE SSSLQ
C-terminal domain of GP41.1	9	MMLKKILKIE ELDERELIDI EVSGNHLFY <u>A</u> <u>NDILTHN</u>
C-terminal domain of GP41.8	36	MCEIFENEID WDEIASIEYV GVEETIDINV TNDRLFF <u>ANG</u> <u>ILTHN</u>
C-terminal domain of NrdJ1	37	MEAKTYIGKL KSRKIVSNED TYDIQTSTHN FF <u>ANDILVHN</u>
C-terminal domain of IMPDH1	38	MKFKLKEITS IETKHYKGKV HDLTVNQDHS YN <u>VRGTVVHN</u>

C-terminal domain of NrdA-2	39	MGLKIIKRES KEPVFDITVK DNSNFF <u>ANNI</u> <u>LVHN</u>
C-terminal domain of Npu DNA-E (Genbank accession ZP_00111398)	40	MIKIATRKYL GKQNVYDIGV ERDHN <u>FALKN</u> <u>GFIASN</u>
C-terminal domain of Ssp DNA-B (Genbank accession Q55418)	41	SPEIEKLSQS DIYWDSIVSI TETGVVEEVF DLTVPGPHNF <u>VANDIIVHN</u>

Underlined sequences correspond to the N1 boxes of the intein N-terminal domains. Double underlined sequences correspond to the C1 boxes of the intein C-terminal domains (e.g., lacking the first amino acid of the extein).

Additional Exemplary N-intein Sequences

[00143] gp 41-2

CLDLKTQVQTQQGLKDISNIQVGDVLV (SEQ ID NO:42)

[00144] gp 41-3

CLDLKTQVQTPQGMKEISNIQVGDVLVLSNTGYNEVLNVFPKSKKKKS (SEQ ID NO:43)

[00145] gp 41-4

CLDLKTQVQTPQGMKEISNIQVGDVLVLSNTGYNEVLNVFPKSKKKKSYKITLEDGKEII
CSEEHLFPTQTGEMNISGGLKEGMCLYVKE (SEQ ID NO:44)

[00146] gp 41-5

CLDLKTQVQTPQGMKEISNIQVGDVLVLSNTGYNEVLNVFPKSKKKKSYKITLEDGKEII
CSEEHLFPTQTGEMNISGGLKEGMCLYVKE (SEQ ID NO:45)

[00147] gp 41-6

SYKITLEDGKEIICSEEHLFPTQNGEVNIKGGGLKEGMCLYVKE (SEQ ID NO:46)

[00148] gp 41-7

MMLKKILKIEELDERELIDIEVSGNH (SEQ ID NO:47)

[00149] NrdA-1

CVAGDTKIKIKYPESVGDQYGTWYWNVLEKEIQIEDLEDYIIMRECEIYDSNAPQIEV
LSYNIETGEQEWPITAFQAQTSPKAKVMKITDEESGKSIVVTPEHQVFTKNRGYVMA
KDLIETDEPIIVNKDMNF (SEQ ID NO:48)

[00150] NrdA-4

CLAGDTTVTVLEGDIVFEMTLENLVSLYKNVFSVSVLSFNPETQKQEFKPVNTAALM
NPESKVLKITDSDTGKSIVCTPDHKVFTKNRGYVIASELNAEDILEIK (SEQ ID NO:49)

[00151] NrdA-5

HTETVRRVGTITAFQAQTSPKSKVMKITDEESGNSIVVTPEHKVFTKNRGYVMAKNLV
ETDELVIN (SEQ IDNO:50)

[00152] NrdA-6

YVCSRDDTTGFKLICTPDHMIYTKNRGYIMAKYKEDDELLINEIHLPT (SEQ ID
NO:51)

[00153] NrdJ-1

CLVGSSEIITRNYGKTTIKEVVEIFDNDKNIQVLA FNTHTDNIEWAPIKAAQLTRPNAE
LVELEIDLHGVTIRCTPDHPVYTKNRGYVRADELTDDELVVAI (SEQ ID NO:52)

[00154] NrdJ-2

CLVGSSEIITRNYGKTTIKEVVEIFDNDKNIQVLA FNTHTDNIEWAPIKAAQLTRPNAE
LVELEINTLHGVTIRCTPDHPVYTKNRDYVRADELTDDELVVAI (SEQ ID NO:53)

Additional Exemplary C-intein Sequences

[00155] gp 41-9

MIMKNRERFITEKILNIEEIDDDLTVDIGMDNEDHYFVANDILTHNT (SEQ ID NO:54)

[00156] IMPDH-2

MKFTLEPITKIDSYEVTAE PVYDIEVENDHSFCV_eNGFVVHNS (SEQ ID NO:55)

[00157] IMPDH-3

MKFKLVEITSKETFNYSQG-VHDLTVEDDHSYSI-NNIVVHNS (SEQ ID NO:56),

[00158] NrdA-3

MLKIEYLEEEIPVYDITVEETHNFFANDILIHNC (SEQ ID NO:57),

[00159] NrdA-5

MLKIEYLEEEIPVYDITVEGTHNLAYSL (SEQ ID NO:58),

[00160] NrdA-6

MGIKIRKLEQNRVYDIKVEKIIIFCNNILVHNC (SEQ ID NO:59), and

[00161] NrdJ-1

MEAKTYIGKLLKSRKIVSNEDTYDIQTSTHNFFANDILVHNS (SEQ ID NO:60).

[00162] The relevant teachings of all patents, published applications and references cited herein are incorporated by reference in their entirety.

[00163] Unless otherwise indicated, all numbers expressing quantities of ingredients, expression conditions, treatment conditions, and so forth used in the specification, including claims, are to be understood as being modified in all instances by the term “about.”

Accordingly, unless otherwise indicated to the contrary, the numerical parameters are approximations and may vary depending upon the desired properties sought to be obtained by the present invention. Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

[00164] While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

CLAIMS

What is claimed is:

1. A fusion protein comprising an N-intein polypeptide and an N-intein solubilization partner joined by a peptide bond, wherein the N-intein solubilization partner has a molecular weight of less than about 15 kDa, an Aliphatic Index value less than about 60, and a Grand Average Hydropathy value less than -1, and enhances solubility of the N-intein polypeptide compared to the N-intein polypeptide expressed in the absence of the solubilization partner.
2. The fusion protein of Claim 1, wherein the N-intein polypeptide is GP41-1 N-intein (SEQ ID NO:1), or a variant thereof.
3. The fusion protein of Claim 2, wherein the variant of GP41-1 N-intein has an amino acid other than cysteine residue at positions 7, 65 and 89 of SEQ ID NO:1.
4. The fusion protein of Claim 3, wherein the variant of GP41-1 N-intein has an alanine at position 7, a threonine residue or an alanine residue at position 65 and either a methionine residue, lysine residue or an asparagine residue at position 89 of SEQ ID NO:1.
5. The fusion protein of any one of Claims 2-4, wherein the variant of GP41-1 N-intein has an amino acid sequence having at least about 90% identity to GP41-1 (SEQ ID NO:1).
6. The fusion protein of any one of Claims 1-5, wherein the N-intein polypeptide lacks an amino acid that is used for attachment of the fusion protein to a solid support.
7. The fusion protein of Claim 6, wherein the amino acid used for attachment of the fusion protein to a solid support is cysteine.
8. The fusion protein of Claim 1, wherein the N-intein polypeptide comprises a sequence selected from SEQ ID NOs:1-8 and 29-56.
9. The fusion protein of any one of Claims 1-8, wherein the N-intein solubilization partner is joined to the N-terminal end of the N-intein polypeptide.

10. The fusion protein of any one of Claims 1-8, wherein the N-intein solubilization partner is joined to the C-terminal end of the N-intein polypeptide.
11. The fusion protein of any of the preceding claims, wherein the N-intein solubilization partner is N-intein solubilization partner 138 (SEQ ID NO:15), or a variant thereof.
12. The fusion protein of Claim 11, wherein the variant of N-intein solubilization partner 138 comprises SEQ ID NO:16, SEQ ID NO:17, or SEQ ID NO:18.
13. The fusion protein of any of the preceding claims, wherein the fusion protein is produced in *E. coli* under conditions in which less than 25% by mass of the fusion protein produced is present in inclusion bodies.
14. The fusion protein of any of the preceding claims, wherein the fusion protein is modified to include a detectable label.
15. The fusion protein of Claim 14, wherein the detectable label is a fluorescent dye.
16. The fusion protein of any of the preceding claims, wherein the fusion protein is expressed in *Escherichia coli*, *Corynebacterium glutamicum*, *Pseudomonas fluorescens*, *Lactococcus lactis*, *Pichia pastoris*, *Saccharomyces cerevisiae*, *Zea mays*, *Nicotinia tabacum*, *Daucus carota*, SF9 cells, CHO cells, NS0 cells, or HEK 293 cells.
17. A nucleic acid encoding the fusion protein of Claims 1-16.
18. The nucleic acid of Claim 17, wherein the nucleic acid is included in an expression vector.
19. The nucleic acid of Claim 17, wherein the nucleic acid is included in a plasmid.
20. A host cell comprising the nucleic acid of Claim 17, 18 or 19.
21. The host cell of Claim 20, wherein the host cell is *E. coli*.
22. An affinity chromatography matrix comprising the fusion protein of any one of Claims 1-16 attached to a solid support.

23. The affinity chromatography matrix of Claim 22, wherein the solid support is a chromatography resin.
24. The affinity chromatography matrix of Claim 23, wherein the chromatography resin includes a hydrophilic polyvinyl ether base.
25. The affinity chromatography matrix of Claim 22, wherein the solid support is a bead, a hollow fiber, a solid fiber, a pad, a gel, a membrane, a cassette, a column, a chip, a slide, a plate or a monolith.
26. The affinity chromatography matrix of Claim 25, wherein the solid support is a magnetic bead.
27. The affinity chromatography matrix of any one of Claims 22-26, wherein the solid support comprises controlled pore glass, silica, zirconium oxide, titanium oxide, agarose, polymethacrylate, polyacrylate, polyacrylamide, polyvinyl alcohol, polystyrene or derivatives thereof.
28. The affinity chromatography matrix of any one of Claims 22-27, wherein the matrix further comprises a spacer molecule between the fusion protein and solid support.
29. The affinity chromatography matrix of any one of Claims 22-28, wherein the fusion protein is attached to the solid support at a single site in the N-intein solubilization partner.
30. The affinity chromatography matrix of any one of Claims 22-28, wherein the fusion protein is attached to the solid support at more than one site in the N-intein solubilization partner.
31. The affinity chromatography matrix of any one of Claims 22-30, wherein the N-intein polypeptide in the fusion protein remains active when the fusion protein is attached to the solid support.
32. The affinity chromatography matrix of any one of Claims 22-31, wherein the N-intein polypeptide in the fusion protein is oriented away from the solid support when the fusion protein is attached to the solid support.

33. A method of affinity purifying a target molecule in a sample, the method comprising:
- a) providing a sample containing a first fusion protein comprising a C-intein polypeptide joined to a target molecule by a peptide bond;
 - b) contacting the sample with an affinity chromatography matrix that comprises a second fusion protein, wherein the second fusion protein comprises an N-intein polypeptide joined by a peptide bond to an N-intein solubilization partner that promotes solubility of the N-intein polypeptide, under conditions in which the C-intein polypeptide in the first fusion protein selectively binds to the N-intein polypeptide in the second fusion protein to form an intein complex that is inactive;
 - c) washing the affinity chromatography matrix containing the inactive intein complex to remove unbound contaminants;
 - d) exposing the intein complex to conditions under which the intein complex is active and cleaves the target molecule from the C-intein polypeptide; and
 - e) recovering the cleaved target molecule.
34. The method of Claim 33, wherein the sample is a crude protein preparation.
35. The method of Claim 33 or 34, wherein the target molecule is a monoclonal antibody to a therapeutic target.
36. The method of Claim 33 or 34, wherein the target molecule is a therapeutic target.
37. The method of Claim any one of Claims 33-36, wherein the conditions under which the C-intein polypeptide in the first fusion protein selectively binds to the N-intein polypeptide in the second fusion protein to form a catalytically-inactive intein complex include:
- a) a temperature in the range of about 4-25 °C, and a buffer comprising 100 mM Tris-HCl, 25 mM NaCl, 0.1mM zinc chloride, pH=9;
 - b) a temperature in the range of about 4-25 °C, and a buffer comprising 50 mM NaAc, 0.5 M NaCl, pH=5; or
 - c) a temperature in the range of about 4-25 °C, and a buffer comprising 0.5 M NaCl, 10 mM Tris-HCl, pH=8.

38. The method of any one of Claims 33-37, wherein the conditions that promote catalytic activity of the intein complex include:
- a) a buffer comprising 50 mM Tris-HCl, pH=7.0, 300 mM NaCl, 1 mM EDTA;
 - b) a buffer comprising 0.3 M L-arginine, 5 mM EDTA, 50 mM phosphate buffer, pH=6.5; or
 - c) a buffer comprising 0.5 M NaCl, 10 mM Tris-HCl, 50 mM DTT, pH=8.0.
39. The method of Claim any one of Claims 33-38, wherein the N-intein solubilization partner has a molecular weight below 15 kDa, an Aliphatic Index value lower than 60, and a Grand Average Hydropathy value less than -1.
40. The method of any one of Claims 33-39, wherein the N-intein solubilization partner is N-intein solubilization partner 138 (SEQ ID NO:15) or a variant thereof.
41. The method of one of Claims 33-40, wherein the N-intein polypeptide is GP41-1 N-intein (SEQ ID NO:1) or a variant thereof, and the C-intein polypeptide is GP41-1 C-intein (SEQ ID NO:9).
42. The method of one of Claims 33-41, further comprising cleaning, regenerating or storing the affinity chromatography matrix for subsequent use.
43. A method of screening for an intein complex that is suitable for use in affinity purification, the method comprising:
- a) contacting a first fusion protein that comprises a C-intein polypeptide joined to a target molecule by a peptide bond with a second fusion protein that comprises an N-intein polypeptide joined to an N-intein solubilization partner by a peptide bond, under conditions in which the C-intein polypeptide in the first fusion protein selectively binds to the N-intein polypeptide in the second fusion protein to form an intein complex; and
 - b) determining whether the target molecule is cleaved from the C-intein polypeptide under conditions which support intein activity, wherein the presence of the cleaved target molecule is indicative of a catalytically-active intein complex.

FIG. 1




FIG. 2






FIG. 3

solubility and cleavage rate for solubilization partners





FIGS. 5A-5B




FIG. 6





FIG. 7



INTERNATIONAL SEARCH REPORT

International application No
PCT/US2015/057125

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C12N9/50 C12N9/00
 ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2013/045632 A1 (ERA BIOTECH S A [ES]) 4 April 2013 (2013-04-04) cited in the application paragraphs [0103], [0104], [0187] example 1	1-32
A	----- GARBE DANIEL ET AL: "Protein trans-splicing on an M13 bacteriophage: towards directed evolution of a semisynthetic split intein by phage display", October 2010 (2010-10), JOURNAL OF PEPTIDE SCIENCE, VOL. 16, NR. 10, SP. ISS. SI, PAGE(S) 575-581, XP002752569, ISSN: 1075-2617(print) page 578, left-hand column, paragraph 1 -----	1-32

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>
---	---

Date of the actual completion of the international search 23 December 2015	Date of mailing of the international search report 31/03/2016
---	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Barnas, Christoph
--	---

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2015/057125

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-32

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-32

A fusion protein comprising an N-intein polypeptide and an N-intein solubilization partner joined by a peptide bond, wherein the N-intein solubilization partner has a molecular weight of less than about 15 kDa, an Aliphatic Index value less than about 60, and a Grand Average Hydropathy value less than -1, and enhances solubility of the N-intein polypeptide compared to the N-intein polypeptide expressed in the absence of the solubilization partner.

2. claims: 33-43

A method of affinity purifying a target molecule in a sample, the method comprising a) providing a sample containing a first fusion protein comprising a C-intein polypeptide joined to a target molecule by a peptide bond and b) contacting the sample with an affinity chromatography matrix that comprises a second fusion protein, wherein the second fusion protein comprises an N-intein polypeptide joined by a peptide bond to an N-intein solubilization partner that promotes solubility of the N-intein polypeptide as described in claim 33 and a method of screening for an intein complex that is suitable for use in affinity purification, the method comprising contacting a first fusion protein that comprises a C-intein polypeptide joined to a target molecule by a peptide bond with a second fusion protein that comprises an N-intein polypeptide joined to an N-intein solubilization partner by a peptide bond as described in claim 43.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2015/057125

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2013045632	A1	04-04-2013	
		AU 2012314355 A1	24-04-2014
		CA 2850411 A1	04-04-2013
		CN 104053779 A	17-09-2014
		EP 2761006 A1	06-08-2014
		JP 2014528720 A	30-10-2014
		KR 20140069313 A	09-06-2014
		US 2015232507 A1	20-08-2015
		WO 2013045632 A1	04-04-2013
